{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:49:40Z","timestamp":1794815380381,"version":"4.9.1"},"reference-count":494,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31925013, 32125016, U20A20393, and W2411011"],"award-info":[{"award-number":["31925013, 32125016, U20A20393, and W2411011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T cell exhaustion is a prevalent phenomenon in chronic infections and tumor microenvironments, severely compromising the effectiveness of antitumor and antiviral immunity. In recent years, there has been significant progress in understanding the underlying mechanisms of T cell exhaustion, including external factors and intrinsic cellular changes that drive this dysfunctional state. Key external factors such as persistent antigen exposure, immune checkpoint signaling, and the cytokine milieu, as well as intrinsic changes such as altered metabolic processes, epigenetic modifications, and transcriptional reprogramming, contribute to T cell dysfunction. Emerging therapies targeting T cell exhaustion aim to restore immune function and enhance antitumor and antiviral immunity. These therapeutic strategies include immune checkpoint inhibition, cytokine therapies, metabolic reprogramming, and cell-based therapies. Despite these advancements, reversing T cell exhaustion presents several challenges, such as individual variability, resistance, and potential side effects. Furthermore, accurately assessing markers of T cell functional recovery and the long-term impacts of these therapeutic approaches remain challenging research areas. This review provides an overview of the history and milestones in T cell exhaustion research; summarizes the mechanisms of T cell exhaustion and its implications in cancer, chronic infections, and autoimmune diseases; discusses advancements and challenges in emerging therapies; and explores future research directions aimed at improving T cell function and enhancing immune responses.<\/jats:p>","DOI":"10.1038\/s41392-025-02327-3","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:09:51Z","timestamp":1767424191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion"],"prefix":"10.1038","volume":"11","author":[{"given":"Yiran","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-8840","authenticated-orcid":false,"given":"Zhengyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-0474","authenticated-orcid":false,"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-7584","authenticated-orcid":false,"given":"Fangfang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"2327_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. T cells in health and disease. Signal Transduct. Target. Ther. 8, 235 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2327_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492\u2013499 (2011).","journal-title":"Nat. Immunol."},{"key":"2327_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486\u2013499 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","volume":"42","author":"A Baessler","year":"2024","unstructured":"Baessler, A. & Vignali, D. A. A. T Cell Exhaustion. Annu. Rev. Immunol. 42, 179\u2013206 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"2327_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","volume":"523","author":"EF McKinney","year":"2015","unstructured":"McKinney, E. F. et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523, 612\u2013616 (2015).","journal-title":"Nature"},{"key":"2327_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coi.2016.09.005","volume":"43","author":"EF McKinney","year":"2016","unstructured":"McKinney, E. F. & Smith, K. G. T cell exhaustion and immune-mediated disease-the potential for therapeutic exhaustion. Curr. Opin. Immunol. 43, 74\u201380 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"2327_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41590-021-00949-7","volume":"22","author":"JL Collier","year":"2021","unstructured":"Collier, J. L. et al. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nat. Immunol. 22, 809\u2013819 (2021).","journal-title":"Nat. Immunol."},{"key":"2327_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbmt.2017.11.022","volume":"24","author":"RL Williams","year":"2018","unstructured":"Williams, R. L. et al. Recipient T cell exhaustion and successful adoptive transfer of haploidentical natural killer cells. Biol. Blood Marrow Transplant. 24, 618\u2013622 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2327_CR9","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1111\/ajt.13702","volume":"16","author":"A Sanchez-Fueyo","year":"2016","unstructured":"Sanchez-Fueyo, A. & Markmann, J. F. Immune exhaustion and transplantation. Am. J. Transpl. 16, 1953\u20131957 (2016).","journal-title":"Am. J. Transpl."},{"key":"2327_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.imlet.2018.08.003","volume":"202","author":"M Shahbazi","year":"2018","unstructured":"Shahbazi, M., Soltanzadeh-Yamchi, M. & Mohammadnia-Afrouzi, M. T cell exhaustion implications during transplantation. Immunol. Lett. 202, 52\u201358 (2018).","journal-title":"Immunol. Lett."},{"key":"2327_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/MOT.0000000000000153","volume":"20","author":"EB Thorp","year":"2015","unstructured":"Thorp, E. B., Stehlik, C. & Ansari, M. J. T-cell exhaustion in allograft rejection and tolerance. Curr. Opin. Organ. Transplant. 20, 37\u201342 (2015).","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"2327_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/nm.2130","volume":"16","author":"EF McKinney","year":"2010","unstructured":"McKinney, E. F. et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat. Med. 16, 586\u2013591 (2010).","journal-title":"Nat. Med."},{"key":"2327_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fimmu.2019.00111","volume":"10","author":"G Pawelec","year":"2019","unstructured":"Pawelec, G. Is there a positive side to T cell exhaustion?. Front. Immunol. 10, 111 (2019).","journal-title":"Front. Immunol."},{"key":"2327_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target. Ther. 6, 412 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2327_CR15","doi-asserted-by":"publisher","first-page":"216894","DOI":"10.1016\/j.canlet.2024.216894","volume":"591","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani, M. et al. Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Lett. 591, 216894 (2024).","journal-title":"Cancer Lett."},{"key":"2327_CR16","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang, Y., Li, Y. & Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6, e1792\u2013e1792 (2015).","journal-title":"Cell Death Dis."},{"key":"2327_CR17","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1172\/JCI120859","volume":"128","author":"JS Tilstra","year":"2018","unstructured":"Tilstra, J. S. et al. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. J. Clin. Invest. 128, 4884\u20134897 (2018).","journal-title":"J. Clin. Invest."},{"key":"2327_CR18","doi-asserted-by":"crossref","unstructured":"Smita, S., Chikina, M., Shlomchik, M. J. & Tilstra, J. S. Heterogeneity and clonality of kidney-infiltrating T cells in murine lupus nephritis. JCI insight 7, e156048 (2022).","DOI":"10.1172\/jci.insight.156048"},{"key":"2327_CR19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41590-022-01210-5","volume":"23","author":"S Grebinoski","year":"2022","unstructured":"Grebinoski, S. et al. Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat. Immunol. 23, 868\u2013877 (2022).","journal-title":"Nat. Immunol."},{"key":"2327_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/978-3-030-41769-7_19","volume":"94","author":"AB Kapingidza","year":"2020","unstructured":"Kapingidza, A. B., Kowal, K. & Chruszcz, M. Antigen-Antibody Complexes. Subcell. Biochem 94, 465\u2013497 (2020).","journal-title":"Subcell. Biochem"},{"key":"2327_CR21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJM198102263040904","volume":"304","author":"RC Wiggins","year":"1981","unstructured":"Wiggins, R. C. & Cochrane, C. G. Immune-complex-mediated biologic effects. N. Engl. J. Med. 304, 518\u2013520 (1981).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2500\/aap.2012.33.3561","volume":"33","author":"A Uzzaman","year":"2012","unstructured":"Uzzaman, A. & Cho, S. H. Chapter 28: Classification of hypersensitivity reactions. Allergy Asthma Proc. 33, 96\u201399 (2012).","journal-title":"Allergy Asthma Proc."},{"key":"2327_CR23","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.108.771170","volume":"120","author":"TN Mayadas","year":"2009","unstructured":"Mayadas, T. N., Tsokos, G. C. & Tsuboi, N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation 120, 2012\u20132024 (2009).","journal-title":"Circulation"},{"key":"2327_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12994","volume":"93","author":"K Roe","year":"2021","unstructured":"Roe, K. An explanation of the pathogenesis of several autoimmune diseases in immuno-compromised individuals. Scand. J. Immunol. 93, e12994 (2021).","journal-title":"Scand. J. Immunol."},{"key":"2327_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108487","volume":"217","author":"L Roncati","year":"2020","unstructured":"Roncati, L. et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin. Immunol. 217, 108487 (2020).","journal-title":"Clin. Immunol."},{"key":"2327_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/jcpt.13560","volume":"47","author":"K Roe","year":"2022","unstructured":"Roe, K. Explanations for 10 of the most puzzling aspects of multisystem inflammatory syndrome and other Kawasaki-like diseases. J. Clin. Pharm. Ther. 47, 539\u2013543 (2022).","journal-title":"J. Clin. Pharm. Ther."},{"key":"2327_CR27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s13577-022-00839-6","volume":"36","author":"K Roe","year":"2023","unstructured":"Roe, K. Accelerated T-cell exhaustion: its potential role in autoimmune disease and hyperinflammatory disease pathogenesis. Hum. Cell 36, 866\u2013869 (2023).","journal-title":"Hum. Cell"},{"key":"2327_CR28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/362758a0","volume":"362","author":"D Moskophidis","year":"1993","unstructured":"Moskophidis, D., Lechner, F., Pircher, H. & Zinkernagel, R. M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362, 758\u2013761 (1993).","journal-title":"Nature"},{"key":"2327_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1099\/0022-1317-76-2-381","volume":"76","author":"D Moskophidis","year":"1995","unstructured":"Moskophidis, D. et al. Role of virus and host variables in virus persistence or immunopathological disease caused by a non-cytolytic virus. J. Gen. Virol. 76, 381\u2013391 (1995).","journal-title":"J. Gen. Virol."},{"key":"2327_CR30","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/0024-3205(94)90087-6","volume":"55","author":"JG Johnson","year":"1994","unstructured":"Johnson, J. G. & Jenkins, M. K. The role of anergy in peripheral T cell unresponsiveness. Life Sci. 55, 1767\u20131780 (1994).","journal-title":"Life Sci."},{"key":"2327_CR31","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1084\/jem.177.5.1517","volume":"177","author":"B Rocha","year":"1993","unstructured":"Rocha, B., Tanchot, C. & Von Boehmer, H. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J. Exp. Med. 177, 1517\u20131521 (1993).","journal-title":"J. Exp. Med."},{"key":"2327_CR32","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1084\/jem.181.3.993","volume":"181","author":"B Rocha","year":"1995","unstructured":"Rocha, B., Grandien, A. & Freitas, A. A. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J. Exp. Med. 181, 993\u20131003 (1995).","journal-title":"J. Exp. Med."},{"key":"2327_CR33","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1084\/jem.187.9.1383","volume":"187","author":"A Gallimore","year":"1998","unstructured":"Gallimore, A. et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187, 1383\u20131393 (1998).","journal-title":"J. Exp. Med."},{"key":"2327_CR34","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","volume":"188","author":"AJ Zajac","year":"1998","unstructured":"Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205\u20132213 (1998).","journal-title":"J. Exp. Med."},{"key":"2327_CR35","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"2327_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nri1349","volume":"4","author":"L Chen","year":"2004","unstructured":"Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4, 336\u2013347 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nri727","volume":"2","author":"AH Sharpe","year":"2002","unstructured":"Sharpe, A. H. & Freeman, G. J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2, 116\u2013126 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR38","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J. 11, 3887\u20133895 (1992).","journal-title":"Embo J."},{"key":"2327_CR39","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nm1482","volume":"12","author":"L Trautmann","year":"2006","unstructured":"Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198\u20131202 (2006).","journal-title":"Nat. Med."},{"key":"2327_CR40","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350\u2013354 (2006).","journal-title":"Nature"},{"key":"2327_CR41","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682\u2013687 (2006).","journal-title":"Nature"},{"key":"2327_CR42","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/nrd.2018.210","volume":"17","author":"J Tang","year":"2018","unstructured":"Tang, J. et al. Trial watch: The clinical trial landscape for PD1\/PDL1 immune checkpoint inhibitors. Nat. Rev. Drug Discov. 17, 854\u2013855 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2327_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","volume":"10","author":"SD Blackburn","year":"2009","unstructured":"Blackburn, S. D. et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29\u201337 (2009).","journal-title":"Nat. Immunol."},{"key":"2327_CR44","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR45","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber, J. et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15, 5591\u20135598 (2009).","journal-title":"Clin. Cancer Res."},{"key":"2327_CR46","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","volume":"21","author":"SJ O\u2019Day","year":"2010","unstructured":"O\u2019Day, S. J. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21, 1712\u20131717 (2010).","journal-title":"Ann. Oncol."},{"key":"2327_CR47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41571-020-00449-x","volume":"18","author":"SH Gohil","year":"2021","unstructured":"Gohil, S. H. et al. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 244\u2013256 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2327_CR48","doi-asserted-by":"crossref","unstructured":"Cheng, C., Chen, W., Jin, H. & Chen, X. A review of single-cell RNA-Seq annotation, integration, and cell-cell communication. Cells 12, 1970 (2023).","DOI":"10.3390\/cells12151970"},{"key":"2327_CR49","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nprot.2017.149","volume":"13","author":"V Svensson","year":"2018","unstructured":"Svensson, V., Vento-Tormo, R. & Teichmann, S. A. Exponential scaling of single-cell RNA-seq in the past decade. Nat. Protoc. 13, 599\u2013604 (2018).","journal-title":"Nat. Protoc."},{"key":"2327_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41551-023-01165-4","volume":"8","author":"E Lugli","year":"2024","unstructured":"Lugli, E., Roederer, M. & Sottile, R. Multipass high-dimensional flow cytometry. Nat. Biomed. Eng. 8, 209\u2013211 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2327_CR51","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"2327_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","journal-title":"Science"},{"key":"2327_CR53","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1034\/j.1600-065X.2003.00009.x","volume":"192","author":"LJ Appleman","year":"2003","unstructured":"Appleman, L. J. & Boussiotis, V. A. T cell anergy and costimulation. Immunol. Rev. 192, 161\u2013180 (2003).","journal-title":"Immunol. Rev."},{"key":"2327_CR54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1146\/annurev.immunol.21.120601.141110","volume":"21","author":"RH Schwartz","year":"2003","unstructured":"Schwartz, R. H. T cell anergy. Annu. Rev. Immunol. 21, 305\u2013334 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"2327_CR55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.0105-2896.2005.00256.x","volume":"205","author":"AN Vallejo","year":"2005","unstructured":"Vallejo, A. N. CD28 extinction in human T cells: Altered functions and the program of T-cell senescence. Immunol. Rev. 205, 158\u2013169 (2005).","journal-title":"Immunol. Rev."},{"key":"2327_CR56","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.4049\/jimmunol.162.11.6572","volume":"162","author":"AN Vallejo","year":"1999","unstructured":"Vallejo, A. N., Brandes, J. C., Weyand, C. M. & Goronzy, J. J. Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence. J. Immunol. 162, 6572\u20136579 (1999).","journal-title":"J. Immunol."},{"key":"2327_CR57","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1182\/blood-2012-03-416040","volume":"120","author":"J Ye","year":"2012","unstructured":"Ye, J. et al. Human regulatory T cells induce T-lymphocyte senescence. Blood 120, 2021\u20132031 (2012).","journal-title":"Blood"},{"key":"2327_CR58","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.4049\/jimmunol.1202369","volume":"190","author":"J Ye","year":"2013","unstructured":"Ye, J. et al. Tumor-derived \u03b3\u03b4 regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J. Immunol. 190, 2403\u20132414 (2013).","journal-title":"J. Immunol."},{"key":"2327_CR59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-0716-1507-2_6","volume":"2325","author":"R Franzin","year":"2021","unstructured":"Franzin, R., Stasi, A., Castellano, G. & Gesualdo, L. Methods for characterization of senescent circulating and tumor-infiltrating T-cells: An overview from multicolor flow cytometry to single-cell RNA sequencing. Methods Mol. Biol. 2325, 79\u201395 (2021).","journal-title":"Methods Mol. Biol."},{"key":"2327_CR60","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","volume":"101","author":"JM Brenchley","year":"2003","unstructured":"Brenchley, J. M. et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101, 2711\u20132720 (2003).","journal-title":"Blood"},{"key":"2327_CR61","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.4049\/jimmunol.1100978","volume":"187","author":"D Di Mitri","year":"2011","unstructured":"Di Mitri, D. et al. Reversible senescence in human CD4+CD45RA+CD27- memory T cells. J. Immunol. 187, 2093\u20132100 (2011).","journal-title":"J. Immunol."},{"key":"2327_CR62","doi-asserted-by":"publisher","first-page":"13414","DOI":"10.1073\/pnas.0706040104","volume":"104","author":"M Heffner","year":"2007","unstructured":"Heffner, M. & Fearon, D. T. Loss of T cell receptor-induced Bmi-1 in the KLRG1+ senescent CD8+ T lymphocyte. Proc. Natl. Acad. Sci. USA104, 13414\u201313419 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Copp\u00e9","year":"2010","unstructured":"Copp\u00e9, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99\u2013118 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"2327_CR64","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41580-024-00727-x","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang, B., Han, J., Elisseeff, J. H. & Demaria, M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat. Rev. Mol. Cell. Biol. 25, 958\u2013978 (2024).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"2327_CR65","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/joim.13141","volume":"288","author":"JL Kirkland","year":"2020","unstructured":"Kirkland, J. L. & Tchkonia, T. Senolytic drugs: From discovery to translation. J. Intern. Med. 288, 518\u2013536 (2020).","journal-title":"J. Intern. Med."},{"key":"2327_CR66","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1172\/JCI26856","volume":"116","author":"DG Brooks","year":"2006","unstructured":"Brooks, D. G., McGavern, D. B. & Oldstone, M. B. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J. Clin. Invest. 116, 1675\u20131685 (2006).","journal-title":"J. Clin. Invest."},{"key":"2327_CR67","doi-asserted-by":"publisher","first-page":"8161","DOI":"10.1128\/JVI.00889-12","volume":"86","author":"JM Angelosanto","year":"2012","unstructured":"Angelosanto, J. M., Blackburn, S. D., Crawford, A. & Wherry, E. J. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J. Virol. 86, 8161\u20138170 (2012).","journal-title":"J. Virol."},{"key":"2327_CR68","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41577-020-0352-z","volume":"20","author":"M Rumpret","year":"2020","unstructured":"Rumpret, M. et al. Functional categories of immune inhibitory receptors. Nat. Rev. Immunol. 20, 771\u2013780 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR69","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.ajpc.2020.100130","volume":"4","author":"A Alfaddagh","year":"2020","unstructured":"Alfaddagh, A. et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. Am. J. Prev. Cardiol. 4, 100130 (2020).","journal-title":"Am. J. Prev. Cardiol."},{"key":"2327_CR70","doi-asserted-by":"crossref","unstructured":"Henein, M. Y., Vancheri, S., Longo, G. & Vancheri, F. The role of inflammation in cardiovascular disease. Int. J. Mol. Sci. 23, 12906 (2022).","DOI":"10.3390\/ijms232112906"},{"key":"2327_CR71","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1126\/science.1230719","volume":"339","author":"FK Swirski","year":"2013","unstructured":"Swirski, F. K. & Nahrendorf, M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339, 161\u2013166 (2013).","journal-title":"Science"},{"key":"2327_CR72","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-020-0352-5","volume":"17","author":"R Saigusa","year":"2020","unstructured":"Saigusa, R., Winkels, H. & Ley, K. T cell subsets and functions in atherosclerosis. Nat. Rev. Cardiol. 17, 387\u2013401 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"2327_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588776","volume":"11","author":"DM Schwartz","year":"2020","unstructured":"Schwartz, D. M. et al. T cells in autoimmunity-associated cardiovascular diseases. Front. Immunol. 11, 588776 (2020).","journal-title":"Front. Immunol."},{"key":"2327_CR74","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38, 2459\u20132472 (2017).","journal-title":"Eur. Heart J."},{"key":"2327_CR75","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","volume":"34","author":"RC Hoogeveen","year":"2014","unstructured":"Hoogeveen, R. C. et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The Atherosclerosis Risk In Communities (ARIC) study. Arterioscler. Thromb. Vasc. Biol. 34, 1069\u20131077 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2327_CR76","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1084\/jem.164.2.661","volume":"164","author":"RS Cotran","year":"1986","unstructured":"Cotran, R. S. et al. Induction and detection of a human endothelial activation antigen in vivo. J. Exp. Med. 164, 661\u2013666 (1986).","journal-title":"J. Exp. Med."},{"key":"2327_CR77","doi-asserted-by":"publisher","first-page":"6641","DOI":"10.1073\/pnas.79.21.6641","volume":"79","author":"JS Pober","year":"1982","unstructured":"Pober, J. S. & Gimbrone, M. A. Jr. Expression of Ia-like antigens by human vascular endothelial cells is inducible in vitro: demonstration by monoclonal antibody binding and immunoprecipitation. Proc. Natl. Acad. Sci. USA79, 6641\u20136645 (1982).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR78","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","volume":"118","author":"MA Gimbrone Jr.","year":"2016","unstructured":"Gimbrone, M. A. Jr. & Garc\u00eda-Carde\u00f1a, G. EndotHelial Cell Dysfunction And The Pathobiology Of Atherosclerosis. Circ. Res. 118, 620\u2013636 (2016).","journal-title":"Circ. Res."},{"key":"2327_CR79","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s44161-022-00208-4","volume":"2","author":"MAC Depuydt","year":"2023","unstructured":"Depuydt, M. A. C. et al. Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells. Nat. Cardiovasc. Res. 2, 112\u2013125 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"2327_CR80","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s44161-023-00376-x","volume":"2","author":"I Raposo-Guti\u00e9rrez","year":"2023","unstructured":"Raposo-Guti\u00e9rrez, I., Rodr\u00edguez-Ronchel, A. & Ramiro, A. R. Atherosclerosis antigens as targets for immunotherapy. Nat. Cardiovasc. Res. 2, 1129\u20131147 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"2327_CR81","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","volume":"25","author":"DM Fernandez","year":"2019","unstructured":"Fernandez, D. M. et al. Single-cell immune landscape of human atherosclerotic plaques. Nat. Med. 25, 1576\u20131588 (2019).","journal-title":"Nat. Med."},{"key":"2327_CR82","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, S. & Zernecke, A. CD8+ T cells in atherosclerosis. Cells 10, 37 (2020).","DOI":"10.3390\/cells10010037"},{"key":"2327_CR83","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.112.001347","volume":"127","author":"T Kyaw","year":"2013","unstructured":"Kyaw, T. et al. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation 127, 1028\u20131039 (2013).","journal-title":"Circulation"},{"key":"2327_CR84","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1161\/01.CIR.102.24.2919","volume":"102","author":"X Zhou","year":"2000","unstructured":"Zhou, X., Nicoletti, A., Elhage, R. & Hansson, G. K. Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102, 2919\u20132922 (2000).","journal-title":"Circulation"},{"key":"2327_CR85","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm1343","volume":"12","author":"H Ait-Oufella","year":"2006","unstructured":"Ait-Oufella, H. et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12, 178\u2013180 (2006).","journal-title":"Nat. Med."},{"key":"2327_CR86","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.tcm.2007.03.001","volume":"17","author":"Z Mallat","year":"2007","unstructured":"Mallat, Z., Ait-Oufella, H. & Tedgui, A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc. Med. 17, 113\u2013118 (2007).","journal-title":"Trends Cardiovasc. Med."},{"key":"2327_CR87","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrcardio.2015.169","volume":"13","author":"X Meng","year":"2016","unstructured":"Meng, X. et al. Regulatory T cells in cardiovascular diseases. Nat. Rev. Cardiol. 13, 167\u2013179 (2016).","journal-title":"Nat. Rev. Cardiol."},{"key":"2327_CR88","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","volume":"31","author":"DX Bu","year":"2011","unstructured":"Bu, D. X. et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 1100\u20131107 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2327_CR89","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1172\/JCI31344","volume":"117","author":"I Gotsman","year":"2007","unstructured":"Gotsman, I. et al. Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice. J. Clin. Invest. 117, 2974\u20132982 (2007).","journal-title":"J. Clin. Invest."},{"key":"2327_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1126761","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Targeting regulatory T cells for cardiovascular diseases. Front. Immunol. 14, 1126761 (2023).","journal-title":"Front. Immunol."},{"key":"2327_CR91","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1093\/cvr\/cvaa264","volume":"117","author":"F Bonacina","year":"2021","unstructured":"Bonacina, F. et al. Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. Cardiovasc. Res. 117, 2069\u20132082 (2021).","journal-title":"Cardiovasc. Res."},{"key":"2327_CR92","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/cvr\/cvu002","volume":"102","author":"T Kita","year":"2014","unstructured":"Kita, T. et al. Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice. Cardiovasc. Res. 102, 107\u2013117 (2014).","journal-title":"Cardiovasc. Res."},{"key":"2327_CR93","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.112.099044","volume":"126","author":"TN Dinh","year":"2012","unstructured":"Dinh, T. N. et al. Cytokine therapy with interleukin-2\/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. C. irculation 126, 1256\u20131266 (2012).","journal-title":"irculation"},{"key":"2327_CR94","doi-asserted-by":"publisher","first-page":"1347987","DOI":"10.3389\/fnagi.2024.1347987","volume":"16","author":"A Adamu","year":"2024","unstructured":"Adamu, A., Li, S., Gao, F. & Xue, G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front. Aging Neurosci. 16, 1347987 (2024).","journal-title":"Front. Aging Neurosci."},{"key":"2327_CR95","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40035-024-00459-0","volume":"13","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Inflammasomes in neurodegenerative diseases. Transl. Neurodegener. 13, 65 (2024).","journal-title":"Transl. Neurodegener."},{"key":"2327_CR96","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-017-0077-5","volume":"6","author":"P Sweeney","year":"2017","unstructured":"Sweeney, P. et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl. Neurodegener. 6, 6 (2017).","journal-title":"Transl. Neurodegener."},{"key":"2327_CR97","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1582-4934.2010.01010.x","volume":"14","author":"KA Jellinger","year":"2010","unstructured":"Jellinger, K. A. Basic mechanisms of neurodegeneration: A critical update. J. Cell Mol. Med. 14, 457\u2013487 (2010).","journal-title":"J. Cell Mol. Med."},{"key":"2327_CR98","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/j.immuni.2022.10.016","volume":"55","author":"X Chen","year":"2022","unstructured":"Chen, X. & Holtzman, D. M. Emerging roles of innate and adaptive immunity in Alzheimer\u2019s disease. Immunity 55, 2236\u20132254 (2022).","journal-title":"Immunity"},{"key":"2327_CR99","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1895-7","volume":"577","author":"D Gate","year":"2020","unstructured":"Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer\u2019s disease. Nature 577, 399\u2013404 (2020).","journal-title":"Nature"},{"key":"2327_CR100","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/brain\/aww270","volume":"140","author":"C Laurent","year":"2017","unstructured":"Laurent, C. et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain 140, 184\u2013200 (2017).","journal-title":"Brain"},{"key":"2327_CR101","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.3233\/JAD-230784","volume":"99","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Characteristics of T Cells in Single-Cell Datasets of Peripheral Blood and Cerebrospinal Fluid in Alzheimer\u2019s Disease Patients. J. Alzheimers Dis. 99, S265\u2013s280 (2024).","journal-title":"J. Alzheimers Dis."},{"key":"2327_CR102","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neurobiolaging.2014.08.008","volume":"36","author":"G Lueg","year":"2015","unstructured":"Lueg, G. et al. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer\u2019s disease. Neurobiol. Aging 36, 81\u201389 (2015).","journal-title":"Neurobiol. Aging"},{"key":"2327_CR103","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11481-012-9402-z","volume":"7","author":"JA Saunders","year":"2012","unstructured":"Saunders, J. A. et al. CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease. J. Neuroimmune Pharmacol. 7, 927\u2013938 (2012).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"2327_CR104","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","volume":"31","author":"B Engelhardt","year":"2009","unstructured":"Engelhardt, B. & Sorokin, L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin. Immunopathol. 31, 497\u2013511 (2009).","journal-title":"Semin. Immunopathol."},{"key":"2327_CR105","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott, N. J. et al. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13\u201325 (2010).","journal-title":"Neurobiol. Dis."},{"key":"2327_CR106","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","volume":"163","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z., Nelson, A. R., Betsholtz, C. & Zlokovic, B. V. Establishment and Dysfunction of the Blood-Brain Barrier. Cell 163, 1064\u20131078 (2015).","journal-title":"Cell"},{"key":"2327_CR107","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nri.2016.144","volume":"17","author":"T Korn","year":"2017","unstructured":"Korn, T. & Kallies, A. T cell responses in the central nervous system. Nat. Rev. Immunol. 17, 179\u2013194 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR108","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.immuni.2004.12.008","volume":"22","author":"T Calzascia","year":"2005","unstructured":"Calzascia, T. et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22, 175\u2013184 (2005).","journal-title":"Immunity"},{"key":"2327_CR109","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nri2550","volume":"9","author":"J Goverman","year":"2009","unstructured":"Goverman, J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9, 393\u2013407 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR110","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1073\/pnas.1211270110","volume":"110","author":"K Baruch","year":"2013","unstructured":"Baruch, K. et al. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc. Natl. Acad. Sci. USA 110, 2264\u20132269 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8967","volume":"6","author":"K Baruch","year":"2015","unstructured":"Baruch, K. et al. Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer\u2019s disease pathology. Nat. Commun. 6, 7967 (2015).","journal-title":"Nat. Commun."},{"key":"2327_CR112","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173\u2013177 (1999).","journal-title":"Nature"},{"key":"2327_CR113","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/nm783","volume":"8","author":"C Hock","year":"2002","unstructured":"Hock, C. et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8, 1270\u20131275 (2002).","journal-title":"Nat. Med."},{"key":"2327_CR114","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"2327_CR115","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","volume":"144","author":"ED Plowey","year":"2022","unstructured":"Plowey, E. D. et al. Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol. 144, 143\u2013153 (2022).","journal-title":"Acta Neuropathol."},{"key":"2327_CR116","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1126\/science.7678183","volume":"259","author":"GS Hotamisligil","year":"1993","unstructured":"Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87\u201391 (1993).","journal-title":"Science"},{"key":"2327_CR117","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11892-005-0071-7","volume":"5","author":"YH Lee","year":"2005","unstructured":"Lee, Y. H. & Pratley, R. E. The evolving role of inflammation in obesity and the metabolic syndrome. Curr. Diab Rep. 5, 70\u201375 (2005).","journal-title":"Curr. Diab Rep."},{"key":"2327_CR118","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05488","volume":"444","author":"JP Despr\u00e9s","year":"2006","unstructured":"Despr\u00e9s, J. P. & Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 444, 881\u2013887 (2006).","journal-title":"Nature"},{"key":"2327_CR119","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1161\/ATVBAHA.107.147835","volume":"27","author":"B Gustafson","year":"2007","unstructured":"Gustafson, B., Hammarstedt, A., Andersson, C. X. & Smith, U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27, 2276\u20132283 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2327_CR120","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.immuni.2022.11.013","volume":"56","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development. Immunity 56, 58\u201377.e11 (2023).","journal-title":"Immunity"},{"key":"2327_CR121","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2337\/db06-1076","volume":"56","author":"CN Lumeng","year":"2007","unstructured":"Lumeng, C. N., Deyoung, S. M., Bodzin, J. L. & Saltiel, A. R. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56, 16\u201323 (2007).","journal-title":"Diabetes"},{"key":"2327_CR122","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1038\/oby.2010.1","volume":"18","author":"KJ Strissel","year":"2010","unstructured":"Strissel, K. J. et al. T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL\/6 mice. Obesity 18, 1918\u20131925 (2010).","journal-title":"Obesity"},{"key":"2327_CR123","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.1964","volume":"15","author":"S Nishimura","year":"2009","unstructured":"Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914\u2013920 (2009).","journal-title":"Nat. Med."},{"key":"2327_CR124","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1172\/JCI28898","volume":"116","author":"H Shi","year":"2006","unstructured":"Shi, H. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116, 3015\u20133025 (2006).","journal-title":"J. Clin. Invest."},{"key":"2327_CR125","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.2337\/db08-0564","volume":"57","author":"MR Dasu","year":"2008","unstructured":"Dasu, M. R. et al. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 57, 3090\u20133098 (2008).","journal-title":"Diabetes"},{"key":"2327_CR126","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1210\/en.2009-0543","volume":"150","author":"M B\u00f6ni-Schnetzler","year":"2009","unstructured":"B\u00f6ni-Schnetzler, M. et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150, 5218\u20135229 (2009).","journal-title":"Endocrinology"},{"key":"2327_CR127","doi-asserted-by":"crossref","unstructured":"Porsche, C. E. et al. Obesity results in adipose tissue T cell exhaustion. JCI insight 6, e139793 (2021).","DOI":"10.1172\/jci.insight.139793"},{"key":"2327_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1012016","volume":"13","author":"LV Vick","year":"2022","unstructured":"Vick, L. V. et al. Aging augments obesity-induced thymic involution and peripheral T cell exhaustion altering the \u201cobesity paradox. Front. Immunol. 13, 1012016 (2022).","journal-title":"Front. Immunol."},{"key":"2327_CR129","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/s41401-023-01207-2","volume":"45","author":"SJ Li","year":"2024","unstructured":"Li, S. J. et al. Autoimmune diseases: Targets, biology, and drug discovery. Acta Pharmacol. Sin. 45, 674\u2013685 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"2327_CR130","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1172\/JCI78089","volume":"125","author":"JA Bluestone","year":"2015","unstructured":"Bluestone, J. A., Bour-Jordan, H., Cheng, M. & Anderson, M. T cells in the control of organ-specific autoimmunity. J. Clin. Invest. 125, 2250\u20132260 (2015).","journal-title":"J. Clin. Invest."},{"key":"2327_CR131","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/ni.3731","volume":"18","author":"AN Theofilopoulos","year":"2017","unstructured":"Theofilopoulos, A. N., Kono, D. H. & Baccala, R. The multiple pathways to autoimmunity. Nat. Immunol. 18, 716\u2013724 (2017).","journal-title":"Nat. Immunol."},{"key":"2327_CR132","doi-asserted-by":"crossref","unstructured":"Bluestone, J. A. & Bour-Jordan, H. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harbor Perspect. Biol. 4, a007542 (2012).","DOI":"10.1101\/cshperspect.a007542"},{"key":"2327_CR133","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.immuni.2024.08.005","volume":"57","author":"C Saggau","year":"2024","unstructured":"Saggau, C. et al. Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity 57, 2416\u20132432.e2418 (2024).","journal-title":"Immunity"},{"key":"2327_CR134","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1172\/JCI126595","volume":"130","author":"AE Wiedeman","year":"2020","unstructured":"Wiedeman, A. E. et al. Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression. J. Clin. Invest. 130, 480\u2013490 (2020).","journal-title":"J. Clin. Invest."},{"key":"2327_CR135","doi-asserted-by":"publisher","first-page":"977394","DOI":"10.3389\/fimmu.2022.977394","volume":"13","author":"Z Gao","year":"2022","unstructured":"Gao, Z., Feng, Y., Xu, J. & Liang, J. T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy. Front. Immunol. 13, 977394 (2022).","journal-title":"Front. Immunol."},{"key":"2327_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744804","volume":"12","author":"MF Huffaker","year":"2021","unstructured":"Huffaker, M. F. et al. Approaches to establishing tolerance in immune mediated diseases. Front. Immunol. 12, 744804 (2021).","journal-title":"Front. Immunol."},{"key":"2327_CR137","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.2337\/db13-0345","volume":"62","author":"KC Herold","year":"2013","unstructured":"Herold, K. C. et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62, 3766\u20133774 (2013).","journal-title":"Diabetes"},{"key":"2327_CR138","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603\u2013613 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR139","doi-asserted-by":"crossref","unstructured":"Long, S. A. et al. Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci. Immunol. 1, eaai7793 (2016).","DOI":"10.1126\/sciimmunol.aai7793"},{"key":"2327_CR140","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(13)70111-6","volume":"1","author":"MR Rigby","year":"2013","unstructured":"Rigby, M. R. et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diab Endocrinol. 1, 284\u2013294 (2013).","journal-title":"Lancet Diab Endocrinol."},{"key":"2327_CR141","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1172\/JCI81722","volume":"125","author":"MR Rigby","year":"2015","unstructured":"Rigby, M. R. et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J. Clin. Invest. 125, 3285\u20133296 (2015).","journal-title":"J. Clin. Invest."},{"key":"2327_CR142","doi-asserted-by":"crossref","unstructured":"Diggins, K. E. et al. Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects. JCI insight 6, e142680 (2021).","DOI":"10.1172\/jci.insight.142680"},{"key":"2327_CR143","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1126\/science.278.5342.1447","volume":"278","author":"ES Rosenberg","year":"1997","unstructured":"Rosenberg, E. S. et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278, 1447\u20131450 (1997).","journal-title":"Science"},{"key":"2327_CR144","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1128\/jvi.68.7.4700-4704.1994","volume":"68","author":"M Battegay","year":"1994","unstructured":"Battegay, M. et al. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J. Virol. 68, 4700\u20134704 (1994).","journal-title":"J. Virol."},{"key":"2327_CR145","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1084\/jem.184.3.863","volume":"184","author":"RD Cardin","year":"1996","unstructured":"Cardin, R. D., Brooks, J. W., Sarawar, S. R. & Doherty, P. C. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J. Exp. Med. 184, 863\u2013871 (1996).","journal-title":"J. Exp. Med."},{"key":"2327_CR146","doi-asserted-by":"publisher","first-page":"8056","DOI":"10.1128\/jvi.68.12.8056-8063.1994","volume":"68","author":"M Matloubian","year":"1994","unstructured":"Matloubian, M., Concepcion, R. J. & Ahmed, R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056\u20138063 (1994).","journal-title":"J. Virol."},{"key":"2327_CR147","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fmicb.2014.00232","volume":"5","author":"S Basmaciogullari","year":"2014","unstructured":"Basmaciogullari, S. & Pizzato, M. The activity of Nef on HIV-1 infectivity. Front. Microbiol. 5, 232 (2014).","journal-title":"Front. Microbiol."},{"key":"2327_CR148","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/34929","volume":"391","author":"KL Collins","year":"1998","unstructured":"Collins, K. L. et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397\u2013401 (1998).","journal-title":"Nature"},{"key":"2327_CR149","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nm0396-338","volume":"2","author":"O Schwartz","year":"1996","unstructured":"Schwartz, O. et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2, 338\u2013342 (1996).","journal-title":"Nat. Med."},{"key":"2327_CR150","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1128\/JVI.75.8.3960-3964.2001","volume":"75","author":"A Preusser","year":"2001","unstructured":"Preusser, A., Briese, L., Baur, A. S. & Willbold, D. Direct in vitro binding of full-length human immunodeficiency virus type 1 Nef protein to CD4 cytoplasmic domain. J. Virol. 75, 3960\u20133964 (2001).","journal-title":"J. Virol."},{"key":"2327_CR151","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1073\/pnas.92.2.349","volume":"92","author":"S Salghetti","year":"1995","unstructured":"Salghetti, S., Mariani, R. & Skowronski, J. Human immunodeficiency virus type 1 Nef and p56lck protein-tyrosine kinase interact with a common element in CD4 cytoplasmic tail. Proc. Natl. Acad. Sci. USA 92, 349\u2013353 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR152","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/0092-8674(94)90360-3","volume":"76","author":"C Aiken","year":"1994","unstructured":"Aiken, C. et al. Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76, 853\u2013864 (1994).","journal-title":"Cell"},{"key":"2327_CR153","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41594-020-0463-z","volume":"27","author":"Y Kwon","year":"2020","unstructured":"Kwon, Y. et al. Structural basis of CD4 downregulation by HIV-1 Nef. Nat. Struct. Mol. Biol. 27, 822\u2013828 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2327_CR154","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016790","volume":"5","author":"LM Traub","year":"2013","unstructured":"Traub, L. M. & Bonifacino, J. S. Cargo recognition in clathrin-mediated endocytosis. Cold Spring Harb. Perspect. Biol. 5, a016790 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2327_CR155","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0092-8674(00)80715-1","volume":"97","author":"V Piguet","year":"1999","unstructured":"Piguet, V. et al. Nef-induced CD4 degradation: A diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell 97, 63\u201373 (1999).","journal-title":"Cell"},{"key":"2327_CR156","doi-asserted-by":"publisher","first-page":"e1000131","DOI":"10.1371\/journal.ppat.1000131","volume":"4","author":"MR Schaefer","year":"2008","unstructured":"Schaefer, M. R. et al. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS Pathog. 4, e1000131 (2008).","journal-title":"PLoS Pathog."},{"key":"2327_CR157","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1093\/emboj\/16.23.6964","volume":"16","author":"ME Greenberg","year":"1997","unstructured":"Greenberg, M. E. et al. Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation. EMBO J. 16, 6964\u20136976 (1997).","journal-title":"EMBO J."},{"key":"2327_CR158","doi-asserted-by":"publisher","first-page":"e01754","DOI":"10.7554\/eLife.01754","volume":"3","author":"X Ren","year":"2014","unstructured":"Ren, X., Park, S. Y., Bonifacino, J. S. & Hurley, J. H. How HIV-1 Nef hijacks the AP-2 clathrin adaptor to downregulate CD4. eLife 3, e01754 (2014).","journal-title":"eLife"},{"key":"2327_CR159","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nsmb.2328","volume":"19","author":"X Jia","year":"2012","unstructured":"Jia, X. et al. Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef. Nat. Struct. Mol. Biol. 19, 701\u2013706 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2327_CR160","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1074-7613(00)80065-5","volume":"10","author":"GB Cohen","year":"1999","unstructured":"Cohen, G. B. et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10, 661\u2013671 (1999).","journal-title":"Immunity"},{"key":"2327_CR161","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1006\/viro.2000.0816","volume":"282","author":"SA Swann","year":"2001","unstructured":"Swann, S. A. et al. HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway. Virology 282, 267\u2013277 (2001).","journal-title":"Virology"},{"key":"2327_CR162","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1128\/JVI.77.5.3041-3049.2003","volume":"77","author":"MR Kasper","year":"2003","unstructured":"Kasper, M. R. & Collins, K. L. Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells. J. Virol. 77, 3041\u20133049 (2003).","journal-title":"J. Virol."},{"key":"2327_CR163","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1083\/jcb.200407031","volume":"167","author":"JF Roeth","year":"2004","unstructured":"Roeth, J. F. et al. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J. Cell Biol. 167, 903\u2013913 (2004).","journal-title":"J. Cell Biol."},{"key":"2327_CR164","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1074\/jbc.M707760200","volume":"283","author":"ER Wonderlich","year":"2008","unstructured":"Wonderlich, E. R., Williams, M. & Collins, K. L. The tyrosine binding pocket in the adaptor protein 1 (AP-1) mu1 subunit is necessary for Nef to recruit AP-1 to the major histocompatibility complex class I cytoplasmic tail. J. Biol. Chem. 283, 3011\u20133022 (2008).","journal-title":"J. Biol. Chem."},{"key":"2327_CR165","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1128\/jvi.63.7.3161-3163.1989","volume":"63","author":"K Takahashi","year":"1989","unstructured":"Takahashi, K. et al. Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus. J. Virol. 63, 3161\u20133163 (1989).","journal-title":"J. Virol."},{"key":"2327_CR166","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1128\/JVI.02577-10","volume":"85","author":"L Li","year":"2011","unstructured":"Li, L. et al. Human herpesvirus 6 suppresses T cell proliferation through induction of cell cycle arrest in infected cells in the G2\/M phase. J. Virol. 85, 6774\u20136783 (2011).","journal-title":"J. Virol."},{"key":"2327_CR167","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1128\/JVI.00106-09","volume":"83","author":"S Gupta","year":"2009","unstructured":"Gupta, S., Agrawal, S. & Gollapudi, S. Differential effect of human herpesvirus 6A on cell division and apoptosis among naive and central and effector memory CD4+ and CD8+ T-cell subsets. J. Virol. 83, 5442\u20135450 (2009).","journal-title":"J. Virol."},{"key":"2327_CR168","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.coviro.2014.10.003","volume":"9","author":"N Frenkel","year":"2014","unstructured":"Frenkel, N., Sharon, E. & Zeigerman, H. Roseoloviruses manipulate host cell cycle. Curr. Opin. Virol. 9, 162\u2013166 (2014).","journal-title":"Curr. Opin. Virol."},{"key":"2327_CR169","doi-asserted-by":"publisher","first-page":"13499","DOI":"10.1128\/JVI.01496-07","volume":"81","author":"G Mlechkovich","year":"2007","unstructured":"Mlechkovich, G. & Frenkel, N. Human herpesvirus 6A (HHV-6A) and HHV-6B alter E2F1\/Rb pathways and E2F1 localization and cause cell cycle arrest in infected T cells. J. Virol. 81, 13499\u201313508 (2007).","journal-title":"J. Virol."},{"key":"2327_CR170","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood.V92.5.1685","volume":"92","author":"P Secchiero","year":"1998","unstructured":"Secchiero, P. et al. Human herpesvirus 7 infection induces profound cell cycle perturbations coupled to disregulation of cdc2 and cyclin B and polyploidization of CD4+ T cells. Blood 92, 1685\u20131696 (1998).","journal-title":"Blood"},{"key":"2327_CR171","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/0008-5472.CAN-07-2282","volume":"68","author":"CL Montes","year":"2008","unstructured":"Montes, C. L. et al. Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res. 68, 870\u2013879 (2008).","journal-title":"Cancer Res."},{"key":"2327_CR172","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.apsb.2021.01.001","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. The biology, function, and applications of exosomes in cancer. Acta Pharm. Sin. B 11, 2783\u20132797 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"2327_CR173","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-017-0269-7","volume":"5","author":"BT Maybruck","year":"2017","unstructured":"Maybruck, B. T., Pfannenstiel, L. W., Diaz-Montero, M. & Gastman, B. R. Tumor-derived exosomes induce CD8+ T cell suppressors. J. Immunother. Cancer 5, 65 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"2327_CR174","doi-asserted-by":"publisher","first-page":"14116","DOI":"10.1073\/pnas.1211910109","volume":"109","author":"CT Ng","year":"2012","unstructured":"Ng, C. T. & Oldstone, M. B. Infected CD8\u03b1- dendritic cells are the predominant source of IL-10 during establishment of persistent viral infection. Proc. Natl. Acad. Sci. USA 109, 14116\u201314121 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR175","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm.2106","volume":"16","author":"EA Said","year":"2010","unstructured":"Said, E. A. et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat. Med. 16, 452\u2013459 (2010).","journal-title":"Nat. Med."},{"key":"2327_CR176","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1084\/jem.20061462","volume":"203","author":"M Ejrnaes","year":"2006","unstructured":"Ejrnaes, M. et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 203, 2461\u20132472 (2006).","journal-title":"J. Exp. Med."},{"key":"2327_CR177","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm1492","volume":"12","author":"DG Brooks","year":"2006","unstructured":"Brooks, D. G. et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12, 1301\u20131309 (2006).","journal-title":"Nat. Med."},{"key":"2327_CR178","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.immuni.2011.04.019","volume":"35","author":"MK Donkor","year":"2011","unstructured":"Donkor, M. K. et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-\u03b21 cytokine. Immunity 35, 123\u2013134 (2011).","journal-title":"Immunity"},{"key":"2327_CR179","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31250-2","volume":"13","author":"F Xie","year":"2022","unstructured":"Xie, F. et al. Breast cancer cell-derived extracellular vesicles promote CD8+\u2009T cell exhaustion via TGF-\u03b2 type II receptor signaling. Nat. Commun. 13, 4461 (2022).","journal-title":"Nat. Commun."},{"key":"2327_CR180","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9, J. & Sheppard, D. TGF-\u03b2 signaling in health and disease. Cell 186, 4007\u20134037 (2023).","journal-title":"Cell"},{"key":"2327_CR181","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-\u03b2 signaling in health, disease, and therapeutics. Signal Transduct. Target. Ther. 9, 61 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2327_CR182","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.molcel.2007.11.039","volume":"29","author":"J Groppe","year":"2008","unstructured":"Groppe, J. et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell 29, 157\u2013168 (2008).","journal-title":"Mol. Cell"},{"key":"2327_CR183","doi-asserted-by":"publisher","first-page":"15679","DOI":"10.1073\/pnas.0908279106","volume":"106","author":"W Zhang","year":"2009","unstructured":"Zhang, W. et al. Single-molecule imaging reveals transforming growth factor-beta-induced type II receptor dimerization. Proc. Natl. Acad. Sci. USA 106, 15679\u201315683 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR184","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/0092-8674(92)90395-S","volume":"71","author":"JL Wrana","year":"1992","unstructured":"Wrana, J. L. et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71, 1003\u20131014 (1992).","journal-title":"Cell"},{"key":"2327_CR185","doi-asserted-by":"publisher","first-page":"27678","DOI":"10.1074\/jbc.272.44.27678","volume":"272","author":"S Abdollah","year":"1997","unstructured":"Abdollah, S. et al. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem. 272, 27678\u201327685 (1997).","journal-title":"J. Biol. Chem."},{"key":"2327_CR186","doi-asserted-by":"publisher","first-page":"10870","DOI":"10.1074\/jbc.M413223200","volume":"280","author":"JY Yi","year":"2005","unstructured":"Yi, J. Y., Shin, I. & Arteaga, C. L. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J. Biol. Chem. 280, 10870\u201310876 (2005).","journal-title":"J. Biol. Chem."},{"key":"2327_CR187","doi-asserted-by":"publisher","first-page":"36803","DOI":"10.1074\/jbc.M005912200","volume":"275","author":"AV Bakin","year":"2000","unstructured":"Bakin, A. V. et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275, 36803\u201336810 (2000).","journal-title":"J. Biol. Chem."},{"key":"2327_CR188","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1074\/jbc.270.13.7117","volume":"270","author":"MT Hartsough","year":"1995","unstructured":"Hartsough, M. T. & Mulder, K. M. Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. J. Biol. Chem. 270, 7117\u20137124 (1995).","journal-title":"J. Biol. Chem."},{"key":"2327_CR189","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1038\/sj.emboj.7601818","volume":"26","author":"MK Lee","year":"2007","unstructured":"Lee, M. K. et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 26, 3957\u20133967 (2007).","journal-title":"EMBO J."},{"key":"2327_CR190","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.immuni.2009.06.015","volume":"31","author":"R Tinoco","year":"2009","unstructured":"Tinoco, R. et al. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 31, 145\u2013157 (2009).","journal-title":"Immunity"},{"key":"2327_CR191","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108791","volume":"41","author":"F Xie","year":"2022","unstructured":"Xie, F. et al. USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-\u03b2 receptor T\u03b2RII. EMBO J. 41, e108791 (2022).","journal-title":"EMBO J."},{"key":"2327_CR192","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.immuni.2006.07.012","volume":"25","author":"JC Marie","year":"2006","unstructured":"Marie, J. C., Liggitt, D. & Rudensky, A. Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 25, 441\u2013454 (2006).","journal-title":"Immunity"},{"key":"2327_CR193","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.immuni.2006.07.011","volume":"25","author":"MO Li","year":"2006","unstructured":"Li, M. O., Sanjabi, S. & Flavell, R. A. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25, 455\u2013471 (2006).","journal-title":"Immunity"},{"key":"2327_CR194","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.immuni.2015.11.008","volume":"43","author":"LK Mackay","year":"2015","unstructured":"Mackay, L. K. et al. T-box transcription factors combine with the cytokines TGF-\u03b2 and IL-15 to control tissue-resident memory T cell fate. Immunity 43, 1101\u20131111 (2015).","journal-title":"Immunity"},{"key":"2327_CR195","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3389\/fimmu.2019.01502","volume":"10","author":"C Harmon","year":"2019","unstructured":"Harmon, C. et al. Liver-derived TGF-\u03b2 maintains the Eomes(hi)Tbet(lo) Phenotype Of Liver Resident Natural Killer Cells. Front. Immunol. 10, 1502 (2019).","journal-title":"Front. Immunol."},{"key":"2327_CR196","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1084\/jem.20030152","volume":"198","author":"W Chen","year":"2003","unstructured":"Chen, W. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198, 1875\u20131886 (2003).","journal-title":"J. Exp. Med."},{"key":"2327_CR197","doi-asserted-by":"crossref","unstructured":"Horn, L. A. et al. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-\u03b2 signaling enables PD-L1-mediated tumor eradication. J. Clin. Invest. 132, e155148 (2022).","DOI":"10.1172\/JCI155148"},{"key":"2327_CR198","doi-asserted-by":"publisher","first-page":"964","DOI":"10.7150\/ijbs.4564","volume":"8","author":"EC Connolly","year":"2012","unstructured":"Connolly, E. C., Freimuth, J. & Akhurst, R. J. Complexities of TGF-\u03b2 targeted cancer therapy. Int. J. Biol. Sci. 8, 964\u2013978 (2012).","journal-title":"Int. J. Biol. Sci."},{"key":"2327_CR199","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin, Y., Xu, J. & Lan, H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J. Hematol. Oncol. 12, 76 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2327_CR200","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan, Y., Yu, Y., Wang, X. & Zhang, T. Tumor-associated macrophages in tumor immunity. Front. Immunol. 11, 583084 (2020).","journal-title":"Front. Immunol."},{"key":"2327_CR201","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang, X., Wang, J., Lu, D. & Xu, X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct. Target. Ther. 6, 75 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2327_CR202","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-07-6621","volume":"68","author":"P Serafini","year":"2008","unstructured":"Serafini, P., Mgebroff, S., Noonan, K. & Borrello, I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68, 5439\u20135449 (2008).","journal-title":"Cancer Res."},{"key":"2327_CR203","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","volume":"222","author":"PC Rodr\u00edguez","year":"2008","unstructured":"Rodr\u00edguez, P. C. & Ochoa, A. C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180\u2013191 (2008).","journal-title":"Immunol. Rev."},{"key":"2327_CR204","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022).","journal-title":"Mol. Cancer"},{"key":"2327_CR205","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"2327_CR206","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer, K. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812\u20133819 (2007).","journal-title":"Blood"},{"key":"2327_CR207","doi-asserted-by":"crossref","unstructured":"Xia, H. et al. Suppression of FIP200 and autophagy by tumor-derived lactate promotes na\u00efve T cell apoptosis and affects tumor immunity. Sci. Immunol. 2, eaan4631 (2017).","DOI":"10.1126\/sciimmunol.aan4631"},{"key":"2327_CR208","doi-asserted-by":"crossref","unstructured":"Vuillefroy de Silly, R. et al. Acidity suppresses CD8+ T-cell function by perturbing IL-2, mTORC1, and c-Myc signaling. EMBO J. 43, 4922-4953 (2024).","DOI":"10.1038\/s44318-024-00235-w"},{"key":"2327_CR209","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41577-020-0406-2","volume":"21","author":"M Certo","year":"2021","unstructured":"Certo, M. et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat. Rev. Immunol. 21, 151\u2013161 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR210","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk7399","volume":"16","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Activation and antitumor immunity of CD8+ T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid. Sci. Transl. Med. 16, eadk7399 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2327_CR211","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.818984","volume":"13","author":"Z Sun","year":"2022","unstructured":"Sun, Z. et al. ConStruction Of A Lactate-related Prognostic Signature For Predicting Prognosis, Tumor Microenvironment, And Immune Response In Kidney Renal Clear Cell Carcinoma. Front. Immunol. 13, 818984 (2022).","journal-title":"Front. Immunol."},{"key":"2327_CR212","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.998140","volume":"13","author":"J Li","year":"2022","unstructured":"Li, J. et al. A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses. Front. Immunol. 13, 998140 (2022).","journal-title":"Front. Immunol."},{"key":"2327_CR213","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41590-023-01738-0","volume":"25","author":"J Ma","year":"2024","unstructured":"Ma, J. et al. Lithium carbonate revitalizes tumor-reactive CD8+ T cells by shunting lactic acid into mitochondria. Nat. Immunol. 25, 552\u2013561 (2024).","journal-title":"Nat. Immunol."},{"key":"2327_CR214","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13046-024-03042-7","volume":"43","author":"D Chen","year":"2024","unstructured":"Chen, D. et al. Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication. J. Exp. Clin. Cancer Res. 43, 125 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2327_CR215","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semcancer.2022.12.001","volume":"88","author":"C Heuser","year":"2023","unstructured":"Heuser, C., Renner, K., Kreutz, M. & Gattinoni, L. Targeting lactate metabolism for cancer immunotherapy - a matter of precision. Semin. Cancer Biol. 88, 32\u201345 (2023).","journal-title":"Semin. Cancer Biol."},{"key":"2327_CR216","doi-asserted-by":"crossref","unstructured":"Tang, Y., Chen, Z., Zuo, Q. & Kang, Y. Regulation of CD8+ T cells by lipid metabolism in cancer progression. Cell. Mol. Immunol. 21, 1215\u20131230 (2024).","DOI":"10.1038\/s41423-024-01224-z"},{"key":"2327_CR217","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","volume":"32","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer cell 32, 377\u2013391.e379 (2017).","journal-title":"Cancer cell"},{"key":"2327_CR218","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-024-07254-x","volume":"629","author":"SB Lacher","year":"2024","unstructured":"Lacher, S. B. et al. PGE(2) limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature 629, 417\u2013425 (2024).","journal-title":"Nature"},{"key":"2327_CR219","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-024-07352-w","volume":"629","author":"M Morotti","year":"2024","unstructured":"Morotti, M. et al. PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature 629, 426\u2013434 (2024).","journal-title":"Nature"},{"key":"2327_CR220","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma, X. et al. Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell. Metab. 30, 143\u2013156.e145 (2019).","journal-title":"Cell. Metab."},{"key":"2327_CR221","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","volume":"569","author":"F Veglia","year":"2019","unstructured":"Veglia, F. et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 569, 73\u201378 (2019).","journal-title":"Nature"},{"key":"2327_CR222","doi-asserted-by":"crossref","unstructured":"Manzo, T. et al. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J. Exp. Med. 217, e20191920 (2020).","DOI":"10.1084\/jem.20191920"},{"key":"2327_CR223","doi-asserted-by":"publisher","first-page":"E6546","DOI":"10.1073\/pnas.1720113115","volume":"115","author":"I Pacella","year":"2018","unstructured":"Pacella, I. et al. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc. Natl. Acad. Sci. USA 115, E6546\u2013e6555 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR224","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","volume":"23","author":"C Glorieux","year":"2024","unstructured":"Glorieux, C., Liu, S., Trachootham, D. & Huang, P. Targeting ROS in cancer: rationale and strategies. Nat. Rev. Drug Discov. 23, 583\u2013606 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2327_CR225","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","volume":"182","author":"CA Corzo","year":"2009","unstructured":"Corzo, C. A. et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182, 5693\u20135701 (2009).","journal-title":"J. Immunol."},{"key":"2327_CR226","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity 54, 1561\u20131577.e1567 (2021).","journal-title":"Immunity"},{"key":"2327_CR227","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang, C. H. et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"2327_CR228","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fimmu.2016.00032","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. & Ertl, H. C. Starved and asphyxiated: How can CD8+ T cells within a tumor microenvironment prevent tumor progression. Front. Immunol. 7, 32 (2016).","journal-title":"Front. Immunol."},{"key":"2327_CR229","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-023-06299-8","volume":"620","author":"C Guo","year":"2023","unstructured":"Guo, C. et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature 620, 200\u2013208 (2023).","journal-title":"Nature"},{"key":"2327_CR230","doi-asserted-by":"publisher","first-page":"e140100","DOI":"10.1172\/JCI140100","volume":"131","author":"DN Edwards","year":"2021","unstructured":"Edwards, D. N. et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J. Clin. Invest. 131, e140100 (2021).","journal-title":"J. Clin. Invest."},{"key":"2327_CR231","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2011.09.021","volume":"35","author":"R Wang","year":"2011","unstructured":"Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871\u2013882 (2011).","journal-title":"Immunity"},{"key":"2327_CR232","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","volume":"63","author":"GC Prendergast","year":"2014","unstructured":"Prendergast, G. C. et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol. Immunother. 63, 721\u2013735 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"2327_CR233","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","volume":"11","author":"M Liu","year":"2018","unstructured":"Liu, M. et al. Targeting the IDO1 pathway in cancer: from bench to bedside. J. Hematol. Oncol. 11, 100 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2327_CR234","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.20020121","volume":"196","author":"G Frumento","year":"2002","unstructured":"Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459\u2013468 (2002).","journal-title":"J. Exp. Med."},{"key":"2327_CR235","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","volume":"18","author":"DA Wainwright","year":"2012","unstructured":"Wainwright, D. A. et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18, 6110\u20136121 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2327_CR236","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1158\/1078-0432.CCR-17-3573","volume":"24","author":"E Ladomersky","year":"2018","unstructured":"Ladomersky, E. et al. IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin. Cancer Res. 24, 2559\u20132573 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2327_CR237","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-018-0600-x","volume":"11","author":"Q Huang","year":"2018","unstructured":"Huang, Q. et al. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. J. Hematol. Oncol. 11, 58 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2327_CR238","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya, S. et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125, 3905\u20133916 (2015).","journal-title":"Blood"},{"key":"2327_CR239","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393\u2013410 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"2327_CR240","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781\u2013790 (2014).","journal-title":"J. Exp. Med."},{"key":"2327_CR241","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc3613","volume":"13","author":"L Antonioli","year":"2013","unstructured":"Antonioli, L., Blandizzi, C., Pacher, P. & Hask\u00f3, G. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13, 842\u2013857 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"2327_CR242","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping, N. E. et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat. Immunol. 22, 205\u2013215 (2021).","journal-title":"Nat. Immunol."},{"key":"2327_CR243","doi-asserted-by":"publisher","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, V. A. Revisiting the PD-1 pathway. Sci. Adv. 6, eabd2712 (2020).","journal-title":"Sci. Adv."},{"key":"2327_CR244","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.it.2019.03.005","volume":"40","author":"T Wartewig","year":"2019","unstructured":"Wartewig, T. & Ruland, J. PD-1 tumor suppressor signaling in T cell lymphomas. Trends Immunol. 40, 403\u2013414 (2019).","journal-title":"Trends Immunol."},{"key":"2327_CR245","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","volume":"23","author":"K Chamoto","year":"2023","unstructured":"Chamoto, K., Yaguchi, T., Tajima, M. & Honjo, T. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nat. Rev. Immunol. 23, 682\u2013695 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR246","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan, B., Halliday, N. & Sansom, D. M. CTLA-4: A moving target in immunotherapy. Blood 131, 58\u201367 (2018).","journal-title":"Blood"},{"key":"2327_CR247","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/328267a0","volume":"328","author":"JF Brunet","year":"1987","unstructured":"Brunet, J. F. et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature 328, 267\u2013270 (1987).","journal-title":"Nature"},{"key":"2327_CR248","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney, L. et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536\u2013541 (2002).","journal-title":"Nature"},{"key":"2327_CR249","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das, M., Zhu, C. & Kuchroo, V. K. Tim-3 and its role in regulating anti-tumor immunity. Immunol. Rev. 276, 97\u2013111 (2017).","journal-title":"Immunol. Rev."},{"key":"2327_CR250","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","volume":"94","author":"B Huard","year":"1997","unstructured":"Huard, B. et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc. Natl. Acad. Sci. USA 94, 5744\u20135749 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR251","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","volume":"169","author":"CJ Workman","year":"2002","unstructured":"Workman, C. J., Dugger, K. J. & Vignali, D. A. Cutting edge: Molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J. Immunol. 169, 5392\u20135395 (2002).","journal-title":"J. Immunol."},{"key":"2327_CR252","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.4049\/jimmunol.161.8.4058","volume":"161","author":"S Hannier","year":"1998","unstructured":"Hannier, S., Tournier, M., Bismuth, G. & Triebel, F. CD3\/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3\/TCR signaling. J. Immunol. 161, 4058\u20134065 (1998).","journal-title":"J. Immunol."},{"key":"2327_CR253","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","volume":"23","author":"C Guy","year":"2022","unstructured":"Guy, C. et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat. Immunol. 23, 757\u2013767 (2022).","journal-title":"Nat. Immunol."},{"key":"2327_CR254","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal, V., Workman, C. J. & Vignali, D. A. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415\u20131422 (2023).","journal-title":"Nat. Immunol."},{"key":"2327_CR255","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu, X. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48\u201357 (2009).","journal-title":"Nat. Immunol."},{"key":"2327_CR256","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/cdd.2012.141","volume":"20","author":"S Liu","year":"2013","unstructured":"Liu, S. et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 20, 456\u2013464 (2013).","journal-title":"Cell Death Differ."},{"key":"2327_CR257","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","volume":"40","author":"N Joller","year":"2014","unstructured":"Joller, N. et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40, 569\u2013581 (2014).","journal-title":"Immunity"},{"key":"2327_CR258","doi-asserted-by":"publisher","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","volume":"289","author":"M Li","year":"2014","unstructured":"Li, M. et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-\u03b3 production of natural killer cells via \u03b2-arrestin 2-mediated negative signaling. J. Biol. Chem. 289, 17647\u201317657 (2014).","journal-title":"J. Biol. Chem."},{"key":"2327_CR259","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106378","volume":"83","author":"DJ Lee","year":"2020","unstructured":"Lee, D. J. The relationship between TIGIT+ regulatory T cells and autoimmune disease. Int. Immunopharmacol. 83, 106378 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2327_CR260","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR261","doi-asserted-by":"publisher","first-page":"eaay0524","DOI":"10.1126\/science.aay0524","volume":"367","author":"MA ElTanbouly","year":"2020","unstructured":"ElTanbouly, M. A. et al. VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance. Science 367, eaay0524 (2020).","journal-title":"Science"},{"key":"2327_CR262","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-020-0296-3","volume":"20","author":"LE Lucca","year":"2020","unstructured":"Lucca, L. E. & Dominguez-Villar, M. Modulation of regulatory T cell function and stability by co-inhibitory receptors. Nat. Rev. Immunol. 20, 680\u2013693 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR263","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41422-020-0323-8","volume":"30","author":"CSN Klose","year":"2020","unstructured":"Klose, C. S. N. & Artis, D. Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity. Cell Res. 30, 475\u2013491 (2020).","journal-title":"Cell Res."},{"key":"2327_CR264","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/JLB.5MA0120-209R","volume":"108","author":"G Ercolano","year":"2020","unstructured":"Ercolano, G. et al. Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells. J. Leukoc. Biol. 108, 723\u2013737 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"2327_CR265","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459\u2013465 (1995).","journal-title":"J. Exp. Med."},{"key":"2327_CR266","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-1-4899-0274-0_22","volume":"406","author":"PJ Noel","year":"1996","unstructured":"Noel, P. J., Boise, L. H. & Thompson, C. B. Regulation of T cell activation by CD28 and CTLA4. Adv. Exp. Med. Biol. 406, 209\u2013217 (1996).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2327_CR267","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"PS Linsley","year":"1991","unstructured":"Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561\u2013569 (1991).","journal-title":"J. Exp. Med."},{"key":"2327_CR268","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.3390\/ijms23073529","volume":"23","author":"G Baldanzi","year":"2022","unstructured":"Baldanzi, G. Immune checkpoint receptors signaling in T cells. Int. J. Mol. Sci. 23, 3529 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2327_CR269","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He, X. & Xu, C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 30, 660\u2013669 (2020).","journal-title":"Cell Res."},{"key":"2327_CR270","doi-asserted-by":"publisher","first-page":"15035","DOI":"10.1038\/nrdp.2015.35","volume":"1","author":"SG Deeks","year":"2015","unstructured":"Deeks, S. G., Overbaugh, J., Phillips, A. & Buchbinder, S. HIV infection. Nat. Rev. Dis. Prim. 1, 15035 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2327_CR271","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.42","volume":"6","author":"B Ye","year":"2015","unstructured":"Ye, B. et al. T-cell exhaustion in chronic hepatitis B infection: Current knowledge and clinical significance. Cell Death Dis. 6, e1694 (2015).","journal-title":"Cell Death Dis."},{"key":"2327_CR272","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","volume":"77","author":"EJ Wherry","year":"2003","unstructured":"Wherry, E. J. et al. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911\u20134927 (2003).","journal-title":"J. Virol."},{"key":"2327_CR273","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"2327_CR274","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41590-018-0045-y","volume":"19","author":"EF McKinney","year":"2018","unstructured":"McKinney, E. F. & Smith, K. G. C. Metabolic exhaustion in infection, cancer and autoimmunity. Nat. Immunol. 19, 213\u2013221 (2018).","journal-title":"Nat. Immunol."},{"key":"2327_CR275","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","volume":"45","author":"B Bengsch","year":"2016","unstructured":"Bengsch, B. et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T cell exhaustion. Immunity 45, 358\u2013373 (2016).","journal-title":"Immunity"},{"key":"2327_CR276","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4049\/jimmunol.1701041","volume":"200","author":"A Sugiura","year":"2018","unstructured":"Sugiura, A. & Rathmell, J. C. Metabolic barriers to T Cell Function In Tumors. J. Immunol. 200, 400\u2013407 (2018).","journal-title":"J. Immunol."},{"key":"2327_CR277","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","volume":"153","author":"CH Chang","year":"2013","unstructured":"Chang, C. H. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239\u20131251 (2013).","journal-title":"Cell"},{"key":"2327_CR278","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","volume":"20","author":"NM Chapman","year":"2020","unstructured":"Chapman, N. M., Boothby, M. R. & Chi, H. Metabolic coordination of T cell quiescence and activation. Nat. Rev. Immunol. 20, 55\u201370 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR279","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.abb2683","volume":"371","author":"K Xu","year":"2021","unstructured":"Xu, K. et al. Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science 371, 405\u2013410 (2021).","journal-title":"Science"},{"key":"2327_CR280","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis, N. et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6, 6692 (2015).","journal-title":"Nat. Commun."},{"key":"2327_CR281","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41423-023-01064-3","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Regulation of CD8+ T memory and exhaustion by the mTOR signals. Cell. Mol. Immunol. 20, 1023\u20131039 (2023).","journal-title":"Cell. Mol. Immunol."},{"key":"2327_CR282","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/imr.12845","volume":"295","author":"H Huang","year":"2020","unstructured":"Huang, H. et al. mTOR signaling at the crossroads of environmental signals and T-cell fate decisions. Immunol. Rev. 295, 15\u201338 (2020).","journal-title":"Immunol. Rev."},{"key":"2327_CR283","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.coi.2017.04.005","volume":"46","author":"H Zeng","year":"2017","unstructured":"Zeng, H. & Chi, H. mTOR signaling in the differentiation and function of regulatory and effector T cells. Curr. Opin. Immunol. 46, 103\u2013111 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"2327_CR284","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.immuni.2010.09.002","volume":"33","author":"JD Powell","year":"2010","unstructured":"Powell, J. D. & Delgoffe, G. M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 33, 301\u2013311 (2010).","journal-title":"Immunity"},{"key":"2327_CR285","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.immuni.2009.10.010","volume":"32","author":"RR Rao","year":"2010","unstructured":"Rao, R. R., Li, Q., Odunsi, K. & Shrikant, P. A. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 32, 67\u201378 (2010).","journal-title":"Immunity"},{"key":"2327_CR286","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","volume":"41","author":"MM Staron","year":"2014","unstructured":"Staron, M. M. et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+ T cells during chronic infection. Immunity 41, 802\u2013814 (2014).","journal-title":"Immunity"},{"key":"2327_CR287","doi-asserted-by":"publisher","first-page":"61.68","DOI":"10.4049\/jimmunol.192.Supp.61.8","volume":"192","author":"M Staron","year":"2014","unstructured":"Staron, M., Gray, S. & Kaech, S. FoxO1 directly regulates the expression of PD-1 and sustains viral specific CD8+ T cell responses during chronic infection (IRM4P.501). J. Immunol. 192, 61.68\u201361.68 (2014).","journal-title":"J. Immunol."},{"key":"2327_CR288","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2018.04.006","volume":"50","author":"CT Luo","year":"2018","unstructured":"Luo, C. T. & Li, M. O. Foxo transcription factors in T cell biology and tumor immunity. Semin. Cancer Biol. 50, 13\u201320 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"2327_CR289","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coi.2017.04.004","volume":"46","author":"EH Ma","year":"2017","unstructured":"Ma, E. H., Poffenberger, M. C., Wong, A. H. & Jones, R. G. The role of AMPK in T cell metabolism and function. Curr. Opin. Immunol. 46, 45\u201352 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"2327_CR290","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.immuni.2014.12.030","volume":"42","author":"J Blagih","year":"2015","unstructured":"Blagih, J. et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42, 41\u201354 (2015).","journal-title":"Immunity"},{"key":"2327_CR291","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature08097","volume":"460","author":"EL Pearce","year":"2009","unstructured":"Pearce, E. L. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103\u2013107 (2009).","journal-title":"Nature"},{"key":"2327_CR292","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/emboj.2011.12","volume":"30","author":"DG Hardie","year":"2011","unstructured":"Hardie, D. G. AMPK and autophagy get connected. EMBO J. 30, 634\u2013635 (2011).","journal-title":"EMBO J."},{"key":"2327_CR293","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/ncb2329","volume":"13","author":"MM Mihaylova","year":"2011","unstructured":"Mihaylova, M. M. & Shaw, R. J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016\u20131023 (2011).","journal-title":"Nat. Cell Biol."},{"key":"2327_CR294","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","volume":"30","author":"DM Gwinn","year":"2008","unstructured":"Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214\u2013226 (2008).","journal-title":"Mol. Cell"},{"key":"2327_CR295","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1748-1716.2009.01972.x","volume":"196","author":"RJ Shaw","year":"2009","unstructured":"Shaw, R. J. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol. 196, 65\u201380 (2009).","journal-title":"Acta Physiol."},{"key":"2327_CR296","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1152\/physrev.00011.2008","volume":"89","author":"GR Steinberg","year":"2009","unstructured":"Steinberg, G. R. & Kemp, B. E. AMPK in health and disease. Physiol. Rev. 89, 1025\u20131078 (2009).","journal-title":"Physiol. Rev."},{"key":"2327_CR297","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco, F. et al. Metabolic and epigenetic regulation of T-cell exhaustion. Nat. Metab. 2, 1001\u20131012 (2020).","journal-title":"Nat. Metab."},{"key":"2327_CR298","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nri1632","volume":"5","author":"F Macian","year":"2005","unstructured":"Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472\u2013484 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR299","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1146\/annurev.immunol.15.1.707","volume":"15","author":"A Rao","year":"1997","unstructured":"Rao, A., Luo, C. & Hogan, P. G. Transcription factors of the NFAT family: Regulation and function. Annu. Rev. Immunol. 15, 707\u2013747 (1997).","journal-title":"Annu. Rev. Immunol."},{"key":"2327_CR300","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8\u207a T cells. Immunity 42, 265\u2013278 (2015).","journal-title":"Immunity"},{"key":"2327_CR301","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"2327_CR302","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"2327_CR303","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","volume":"571","author":"F Alfei","year":"2019","unstructured":"Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265\u2013269 (2019).","journal-title":"Nature"},{"key":"2327_CR304","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-019-0979-8","volume":"567","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature 567, 525\u2013529 (2019).","journal-title":"Nature"},{"key":"2327_CR305","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019).","journal-title":"Nature"},{"key":"2327_CR306","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.immuni.2009.06.019","volume":"31","author":"H Shin","year":"2009","unstructured":"Shin, H. et al. A role for the transcriptional repressor Blimp-1 in CD8+ T cell exhaustion during chronic viral infection. Immunity 31, 309\u2013320 (2009).","journal-title":"Immunity"},{"key":"2327_CR307","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1126\/science.1175870","volume":"325","author":"RJ Johnston","year":"2009","unstructured":"Johnston, R. J. et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325, 1006\u20131010 (2009).","journal-title":"Science"},{"key":"2327_CR308","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev.immunol.26.021607.090241","volume":"26","author":"G Martins","year":"2008","unstructured":"Martins, G. & Calame, K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol. 26, 133\u2013169 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"2327_CR309","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109120","volume":"35","author":"LM McLane","year":"2021","unstructured":"McLane, L. M. et al. Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. Cell Rep. 35, 109120 (2021).","journal-title":"Cell Rep."},{"key":"2327_CR310","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aae0491","volume":"354","author":"DR Sen","year":"2016","unstructured":"Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 1165\u20131169 (2016).","journal-title":"Science"},{"key":"2327_CR311","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41590-024-01961-3","volume":"25","author":"SA Weiss","year":"2024","unstructured":"Weiss, S. A. et al. Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control. Nat. Immunol. 25, 1871\u20131883 (2024).","journal-title":"Nat. Immunol."},{"key":"2327_CR312","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.immuni.2023.05.008","volume":"56","author":"AE Baxter","year":"2023","unstructured":"Baxter, A. E. et al. The SWI\/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells. Immunity 56, 1320\u20131340.e1310 (2023).","journal-title":"Immunity"},{"key":"2327_CR313","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.V128.22.2918.2918","volume":"128","author":"B Kahali","year":"2016","unstructured":"Kahali, B., Sinha, C., Ritter, A. & Cunningham, L. C. SWI\/SNF Chromatin Remodeling Complex Regulates the Expression of PD-L1 in a Spatio-Temporal Manner in Acute Lymphoblastic Leukemia (ALL) in Vitro. Blood 128, 2918 (2016).","journal-title":"Blood"},{"key":"2327_CR314","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","volume":"170","author":"HE Ghoneim","year":"2017","unstructured":"Ghoneim, H. E. et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell 170, 142\u2013157.e119 (2017).","journal-title":"Cell"},{"key":"2327_CR315","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","volume":"585","author":"Y Bian","year":"2020","unstructured":"Bian, Y. et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature 585, 277\u2013282 (2020).","journal-title":"Nature"},{"key":"2327_CR316","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41573-019-00214-5","volume":"19","author":"K Garber","year":"2020","unstructured":"Garber, K. Immune agonist antibodies face critical test. Nat. Rev. Drug Discov. 19, 3\u20135 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2327_CR317","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrd.2018.75","volume":"17","author":"PA Mayes","year":"2018","unstructured":"Mayes, P. A., Hance, K. W. & Hoos, A. The promise and challenges of immune agonist antibody development in cancer. Nat. Rev. Drug Discov. 17, 509\u2013527 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2327_CR318","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"2327_CR319","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345\u2013362 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2327_CR320","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S1470-2045(19)30483-8","volume":"20","author":"JC Hassel","year":"2019","unstructured":"Hassel, J. C. 5-year results for pembrolizumab treatment of advanced melanoma. Lancet Oncol. 20, 1187\u20131189 (2019).","journal-title":"Lancet Oncol."},{"key":"2327_CR321","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127\u2013137 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2327_CR322","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR323","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/gutjnl-2022-327059","volume":"72","author":"CY Meng","year":"2023","unstructured":"Meng, C. Y. et al. Engineered anti-PDL1 with IFN\u03b1 targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut 72, 1544\u20131554 (2023).","journal-title":"Gut"},{"key":"2327_CR324","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","volume":"138","author":"P Fisicaro","year":"2010","unstructured":"Fisicaro, P. et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138, 682\u2013693 (2010).","journal-title":"Gastroenterology"},{"key":"2327_CR325","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/JCI121957","volume":"128","author":"L Salimzadeh","year":"2018","unstructured":"Salimzadeh, L. et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Invest. 128, 4573\u20134587 (2018).","journal-title":"J. Clin. Invest."},{"key":"2327_CR326","doi-asserted-by":"publisher","first-page":"1061394","DOI":"10.3389\/fimmu.2022.1061394","volume":"13","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. TGF-\u03b2: A novel predictor and target for anti-PD-1\/PD-L1 therapy. Front. Immunol. 13, 1061394 (2022).","journal-title":"Front. Immunol."},{"key":"2327_CR327","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng, D. et al. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol. Cancer 21, 104 (2022).","journal-title":"Mol. Cancer"},{"key":"2327_CR328","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45996-4","volume":"15","author":"EL Hardaker","year":"2024","unstructured":"Hardaker, E. L. et al. The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nat. Commun. 15, 1700 (2024).","journal-title":"Nat. Commun."},{"key":"2327_CR329","doi-asserted-by":"publisher","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta, M. T., Antignani, A. & Fitzgerald, D. J. Managing the TME to improve the efficacy of cancer therapy. Front. Immunol. 13, 954992 (2022).","journal-title":"Front. Immunol."},{"key":"2327_CR330","doi-asserted-by":"publisher","first-page":"28960","DOI":"10.1073\/pnas.2013644117","volume":"117","author":"D Biasci","year":"2020","unstructured":"Biasci, D. et al. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc. Natl. Acad. Sci. Usa. 117, 28960\u201328970 (2020).","journal-title":"Proc. Natl. Acad. Sci. Usa."},{"key":"2327_CR331","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack. Proc. Natl. Acad. Sci. USA. 119, e2119463119 (2022).","DOI":"10.1073\/pnas.2119463119"},{"key":"2327_CR332","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR333","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","volume":"76","author":"A Stiff","year":"2016","unstructured":"Stiff, A. et al. Myeloid-derived suppressor cells express Bruton\u2019s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res 76, 2125\u20132136 (2016).","journal-title":"Cancer Res"},{"key":"2327_CR334","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1007\/s00262-023-03497-1","volume":"72","author":"SH Sun","year":"2023","unstructured":"Sun, S. H. et al. BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy. Cancer Immunol. Immunother. 72, 3461\u20133474 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"2327_CR335","doi-asserted-by":"publisher","first-page":"134ra162","DOI":"10.1126\/scitranslmed.3003330","volume":"4","author":"AJ Rech","year":"2012","unstructured":"Rech, A. J. et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 4, 134ra162 (2012).","journal-title":"Sci. Transl. Med."},{"key":"2327_CR336","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1073\/pnas.1820388116","volume":"116","author":"M Onda","year":"2019","unstructured":"Onda, M., Kobayashi, K. & Pastan, I. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. Proc. Natl. Acad. Sci. USA 116, 4575\u20134582 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR337","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s43018-022-00382-1","volume":"3","author":"V Anagnostou","year":"2022","unstructured":"Anagnostou, V., Bardelli, A., Chan, T. A. & Turajlic, S. The status of tumor mutational burden and immunotherapy. Nat. Cancer 3, 652\u2013656 (2022).","journal-title":"Nat. Cancer"},{"key":"2327_CR338","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer cell 39, 154\u2013173 (2021).","journal-title":"Cancer cell"},{"key":"2327_CR339","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"2327_CR340","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2083755","volume":"11","author":"AD Staniszewska","year":"2022","unstructured":"Staniszewska, A. D. et al. PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. Oncoimmunology 11, 2083755 (2022).","journal-title":"Oncoimmunology"},{"key":"2327_CR341","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.1021\/acsnano.1c09794","volume":"16","author":"D Liu","year":"2022","unstructured":"Liu, D. et al. Nano-codelivery of temozolomide and siPD-L1 to reprogram the drug-resistant and immunosuppressive microenvironment in orthotopic glioblastoma. ACS Nano 16, 7409\u20137427 (2022).","journal-title":"ACS Nano"},{"key":"2327_CR342","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1158\/1078-0432.CCR-22-3229","volume":"29","author":"MA Velez","year":"2023","unstructured":"Velez, M. A. & Garon, E. B. Is there a place for temozolomide plus nivolumab among neuroendocrine neoplasms?. Clin. Cancer Res. 29, 691\u2013693 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2327_CR343","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger, S. et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 7, 1420\u20131435 (2017).","journal-title":"Cancer Discov."},{"key":"2327_CR344","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501 (2016).","journal-title":"Nat. Commun."},{"key":"2327_CR345","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2327_CR346","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","volume":"61","author":"RR Ji","year":"2012","unstructured":"Ji, R. R. et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019\u20131031 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"2327_CR347","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR348","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja, L. et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review. Ann. Oncol. 28, 2377\u20132385 (2017).","journal-title":"Ann. Oncol."},{"key":"2327_CR349","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2327_CR350","doi-asserted-by":"publisher","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra245 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2327_CR351","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling, L. et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J. Immunother. Cancer 4, 50 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"2327_CR352","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","volume":"166","author":"SK Quirk","year":"2015","unstructured":"Quirk, S. K., Shure, A. K. & Agrawal, D. K. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl. Res. 166, 412\u2013424 (2015).","journal-title":"Transl. Res."},{"key":"2327_CR353","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.989431","volume":"13","author":"LI Yousif","year":"2022","unstructured":"Yousif, L. I. et al. The role of immune checkpoints in cardiovascular disease. Front. Pharmacol. 13, 989431 (2022).","journal-title":"Front. Pharmacol."},{"key":"2327_CR354","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579\u20131589 (2018).","journal-title":"Lancet Oncol."},{"key":"2327_CR355","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 4, 1721\u20131728 (2018).","journal-title":"JAMA Oncol."},{"key":"2327_CR356","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 112, 90\u201392 (2021).","journal-title":"Actas Dermosifiliogr."},{"key":"2327_CR357","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00380-1","volume":"7","author":"RJ Verheijden","year":"2023","unstructured":"Verheijden, R. J. et al. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis. Oncol. 7, 41 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"2327_CR358","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","volume":"17","author":"AY Chen","year":"2021","unstructured":"Chen, A. Y., Wolchok, J. D. & Bass, A. R. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat. Rev. Rheumatol. 17, 213\u2013223 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2327_CR359","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02358-7","volume":"8","author":"F Bertrand","year":"2017","unstructured":"Bertrand, F. et al. TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat. Commun. 8, 2256 (2017).","journal-title":"Nat. Commun."},{"key":"2327_CR360","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428\u2013432 (2019).","journal-title":"Nature"},{"key":"2327_CR361","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","volume":"26","author":"RJ Verheijden","year":"2020","unstructured":"Verheijden, R. J. et al. Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry. Clin. Cancer Res. 26, 2268\u20132274 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2327_CR362","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1158\/1078-0432.CCR-15-2471","volume":"21","author":"E Arriola","year":"2015","unstructured":"Arriola, E. et al. Infliximab for IPILIMUMAB-related colitis-letter. Clin. Cancer Res. 21, 5642\u20135643 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2327_CR363","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.3390\/curroncol28030201","volume":"28","author":"DV Araujo","year":"2021","unstructured":"Araujo, D. V. et al. Real world outcomes and hepatotoxicity of infliximab in the treatment of steroid-refractory immune-related adverse events. Curr. Oncol. 28, 2173\u20132179 (2021).","journal-title":"Curr. Oncol."},{"key":"2327_CR364","doi-asserted-by":"publisher","first-page":"e002742","DOI":"10.1136\/jitc-2021-002742","volume":"9","author":"JL Alexander","year":"2021","unstructured":"Alexander, J. L. et al. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. J. Immunother. Cancer 9, e002742 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2327_CR365","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","volume":"93","author":"C Campochiaro","year":"2021","unstructured":"Campochiaro, C. et al. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur. J. Intern. Med. 93, 87\u201394 (2021).","journal-title":"Eur. J. Intern. Med."},{"key":"2327_CR366","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","volume":"157","author":"F Dimitriou","year":"2021","unstructured":"Dimitriou, F. et al. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur. J. Cancer 157, 214\u2013224 (2021).","journal-title":"Eur. J. Cancer"},{"key":"2327_CR367","doi-asserted-by":"crossref","unstructured":"Holmstroem, R. B. et al. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J. Immunother. Cancer 10, e005111 (2022).","DOI":"10.1136\/jitc-2022-005111"},{"key":"2327_CR368","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade8520","volume":"384","author":"J Zak","year":"2024","unstructured":"Zak, J. et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science 384, eade8520 (2024).","journal-title":"Science"},{"key":"2327_CR369","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384, eadf1329 (2024).","journal-title":"Science"},{"key":"2327_CR370","doi-asserted-by":"publisher","first-page":"e1291106","DOI":"10.1080\/2162402X.2017.1291106","volume":"6","author":"C Lu","year":"2017","unstructured":"Lu, C. et al. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology 6, e1291106 (2017).","journal-title":"Oncoimmunology"},{"key":"2327_CR371","doi-asserted-by":"publisher","first-page":"e1458810","DOI":"10.1080\/2162402X.2018.1458810","volume":"7","author":"S Langdon","year":"2018","unstructured":"Langdon, S. et al. Combination of dual mTORC1\/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology 7, e1458810 (2018).","journal-title":"Oncoimmunology"},{"key":"2327_CR372","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.793831","volume":"12","author":"X Bai","year":"2021","unstructured":"Bai, X. et al. Improvement of PD-1 blockade efficacy and elimination of immune-related gastrointestinal adverse effect by mTOR inhibitor. Front. Immunol. 12, 793831 (2021).","journal-title":"Front. Immunol."},{"key":"2327_CR373","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01624-5","volume":"39","author":"W Xia","year":"2022","unstructured":"Xia, W. et al. The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8+ T cells in bladder cancer. Med. Oncol. 39, 37 (2022).","journal-title":"Med. Oncol."},{"key":"2327_CR374","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2327_CR375","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217\u20131238 (2022).","journal-title":"Ann. Oncol."},{"key":"2327_CR376","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.coi.2007.06.004","volume":"19","author":"H Shin","year":"2007","unstructured":"Shin, H. & Wherry, E. J. CD8 T cell dysfunction during chronic viral infection. Curr. Opin. Immunol. 19, 408\u2013415 (2007).","journal-title":"Curr. Opin. Immunol."},{"key":"2327_CR377","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper, D. J. & Balkwill, F. R. Harnessing cytokines and chemokines for cancer therapy. Nat. Rev. Clin. Oncol. 19, 237\u2013253 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2327_CR378","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2051-1426-2-13","volume":"2","author":"R Payne","year":"2014","unstructured":"Payne, R. et al. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J. Immunother. Cancer 2, 13 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"2327_CR379","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","volume":"23","author":"DF McDermott","year":"2005","unstructured":"McDermott, D. F. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133\u2013141 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2327_CR380","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","volume":"2","author":"JP Dutcher","year":"2014","unstructured":"Dutcher, J. P. et al. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J. Immunother. Cancer 2, 26 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"2327_CR381","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104614","volume":"92","author":"L Ou","year":"2023","unstructured":"Ou, L. et al. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine 92, 104614 (2023).","journal-title":"EBioMedicine"},{"key":"2327_CR382","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nri2970","volume":"11","author":"CL Mackall","year":"2011","unstructured":"Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11, 330\u2013342 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR383","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cell.2011.01.011","volume":"144","author":"M Pellegrini","year":"2011","unstructured":"Pellegrini, M. et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 144, 601\u2013613 (2011).","journal-title":"Cell"},{"key":"2327_CR384","doi-asserted-by":"publisher","first-page":"eabb1269","DOI":"10.1126\/scisignal.abb1269","volume":"14","author":"A Koyas","year":"2021","unstructured":"Koyas, A. et al. Interleukin-7 protects CD8+ T cells from adenosine-mediated immunosuppression. Sci. Signal. 14, eabb1269 (2021).","journal-title":"Sci. Signal."},{"key":"2327_CR385","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma, S., Caligiuri, M. A. & Yu, J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol. 43, 833\u2013847 (2022).","journal-title":"Trends Immunol."},{"key":"2327_CR386","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","volume":"11","author":"TA Waldmann","year":"2020","unstructured":"Waldmann, T. A., Dubois, S., Miljkovic, M. D. & Conlon, K. C. IL-15 iN The Combination Immunotherapy Of Cancer. Front. Immunol. 11, 868 (2020).","journal-title":"Front. Immunol."},{"key":"2327_CR387","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101531","volume":"5","author":"W Shi","year":"2024","unstructured":"Shi, W. et al. Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell Rep. Med. 5, 101531 (2024).","journal-title":"Cell Rep. Med."},{"key":"2327_CR388","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-024-02060-1","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam, S. J. Nogapendekin alfa inbakicept: First approval. Drugs 84, 867\u2013874 (2024).","journal-title":"Drugs"},{"key":"2327_CR389","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR390","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","volume":"37","author":"BA Baldo","year":"2014","unstructured":"Baldo, B. A. Side effects of cytokines approved for therapy. Drug Saf. 37, 921\u2013943 (2014).","journal-title":"Drug Saf."},{"key":"2327_CR391","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911223","volume":"12","author":"L Huyghe","year":"2020","unstructured":"Huyghe, L. et al. Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies. EMBO Mol. Med. 12, e11223 (2020).","journal-title":"EMBO Mol. Med."},{"key":"2327_CR392","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1126\/science.abb5607","volume":"370","author":"AW Li","year":"2020","unstructured":"Li, A. W. & Lim, W. A. Engineering cytokines and cytokine circuits. Science 370, 1034\u20131035 (2020).","journal-title":"Science"},{"key":"2327_CR393","doi-asserted-by":"crossref","unstructured":"Shi, W., Liu, N. & Lu, H. Advancements and challenges in immunocytokines: A new arsenal against cancer. Acta Pharm. Sin. B 14, 4649-4664 (2024).","DOI":"10.1016\/j.apsb.2024.07.024"},{"key":"2327_CR394","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1002569107","volume":"107","author":"C Krieg","year":"2010","unstructured":"Krieg, C., L\u00e9tourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl. Acad. Sci. USA 107, 11906\u201311911 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR395","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrg3927","volume":"16","author":"MS Packer","year":"2015","unstructured":"Packer, M. S. & Liu, D. R. Methods for the directed evolution of proteins. Nat. Rev. Genet. 16, 379\u2013394 (2015).","journal-title":"Nat. Rev. Genet."},{"key":"2327_CR396","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10975","volume":"484","author":"AM Levin","year":"2012","unstructured":"Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine. Nature 484, 529\u2013533 (2012).","journal-title":"Nature"},{"key":"2327_CR397","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","volume":"68","author":"H Singh","year":"2008","unstructured":"Singh, H. et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 68, 2961\u20132971 (2008).","journal-title":"Cancer Res."},{"key":"2327_CR398","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3016","volume":"8","author":"JJ Peng","year":"2023","unstructured":"Peng, J. J. et al. Metabolic challenges and interventions in CAR T cell therapy. Sci. Immunol. 8, eabq3016 (2023).","journal-title":"Sci. Immunol."},{"key":"2327_CR399","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR400","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR401","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145\u20132154 (2022).","journal-title":"Nat. Med."},{"key":"2327_CR402","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR403","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504\u20131506 (2018).","journal-title":"Nat. Med."},{"key":"2327_CR404","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 Immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"2327_CR405","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","volume":"34","author":"M Asnani","year":"2020","unstructured":"Asnani, M. et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia 34, 1202\u20131207 (2020).","journal-title":"Leukemia"},{"key":"2327_CR406","doi-asserted-by":"publisher","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).","journal-title":"Sci. Signal."},{"key":"2327_CR407","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell, K. M. & Kochenderfer, J. N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18, 715\u2013727 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2327_CR408","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","volume":"15","author":"J Tan","year":"2022","unstructured":"Tan, J. et al. Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. J. Hematol. Oncol. 15, 39 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2327_CR409","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","volume":"10","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects. Protein Cell 10, 764\u2013769 (2019).","journal-title":"Protein Cell"},{"key":"2327_CR410","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"2327_CR411","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR412","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso, B. et al. The other side of CAR T-cell therapy: Cytokine release syndrome, neurologic toxicity, and financial burden. Am. Soc. Clin. Oncol. Educ. Book 39, 433\u2013444 (2019).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"2327_CR413","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nyas.14724","volume":"1510","author":"M Mirzaee Godarzee","year":"2022","unstructured":"Mirzaee Godarzee, M. et al. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy. Ann. N. Y. Acad. Sci. 1510, 18\u201335 (2022).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2327_CR414","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"2327_CR415","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2327_CR416","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2327_CR417","doi-asserted-by":"publisher","first-page":"129","DOI":"10.20892\/j.issn.2095-3941.2022.0585","volume":"20","author":"P Li","year":"2023","unstructured":"Li, P. et al. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Biol. Med. 20, 129\u2013146 (2023).","journal-title":"Cancer Biol. Med."},{"key":"2327_CR418","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","volume":"46","author":"AD Hughes","year":"2024","unstructured":"Hughes, A. D., Teachey, D. T. & Diorio, C. Riding the storm: Managing cytokine-related toxicities in CAR-T cell therapy. Semin. Immunopathol. 46, 5 (2024).","journal-title":"Semin. Immunopathol."},{"key":"2327_CR419","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR420","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le, R. Q. et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23, 943\u2013947 (2018).","journal-title":"Oncologist"},{"key":"2327_CR421","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jha2.356","volume":"3","author":"U Patel","year":"2022","unstructured":"Patel, U. et al. CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem 3, 24\u201331 (2022).","journal-title":"EJHaem"},{"key":"2327_CR422","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick, K., O\u2019Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. Annu. Rev. Med. 68, 139\u2013152 (2017).","journal-title":"Annu. Rev. Med."},{"key":"2327_CR423","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1158\/0008-5472.CAN-14-1831","volume":"75","author":"X Zheng","year":"2015","unstructured":"Zheng, X. et al. Targeting LUNX inhibits non-small cell lung cancer growth and metastasis. Cancer Res. 75, 1080\u20131090 (2015).","journal-title":"Cancer Res."},{"key":"2327_CR424","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04433-8","volume":"21","author":"AG Simon","year":"2023","unstructured":"Simon, A. G. et al. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis. J. Transl. Med. 21, 552 (2023).","journal-title":"J. Transl. Med."},{"key":"2327_CR425","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jgg.2021.02.011","volume":"48","author":"P Zhao","year":"2021","unstructured":"Zhao, P., Jiang, D., Huang, Y. & Chen, C. EphA2: A promising therapeutic target in breast cancer. J. Genet. Genomics 48, 261\u2013267 (2021).","journal-title":"J. Genet. Genomics"},{"key":"2327_CR426","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40115-1","volume":"14","author":"EHJ Lee","year":"2023","unstructured":"Lee, E. H. J. et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat. Commun. 14, 4737 (2023).","journal-title":"Nat. Commun."},{"key":"2327_CR427","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7336","volume":"14","author":"IY Jung","year":"2022","unstructured":"Jung, I. Y. et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci. Transl. Med. 14, eabn7336 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2327_CR428","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13046-023-02838-3","volume":"42","author":"A Timpanaro","year":"2023","unstructured":"Timpanaro, A. et al. CD276-CAR T cells and Dual-CAR T cells targeting CD276\/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models. J. Exp. Clin. Cancer Res. 42, 293 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2327_CR429","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00238-9","volume":"8","author":"Q Liao","year":"2020","unstructured":"Liao, Q. et al. Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing. Biomark. Res. 8, 56 (2020).","journal-title":"Biomark. Res."},{"key":"2327_CR430","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100227","volume":"2","author":"P Kosti","year":"2021","unstructured":"Kosti, P. et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep. Med. 2, 100227 (2021).","journal-title":"Cell Rep. Med."},{"key":"2327_CR431","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin, L. et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat. Commun. 10, 4016 (2019).","journal-title":"Nat. Commun."},{"key":"2327_CR432","doi-asserted-by":"publisher","first-page":"e1395997","DOI":"10.1080\/2162402X.2017.1395997","volume":"7","author":"EK Moon","year":"2018","unstructured":"Moon, E. K. et al. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology 7, e1395997 (2018).","journal-title":"Oncoimmunology"},{"key":"2327_CR433","doi-asserted-by":"publisher","first-page":"100543","DOI":"10.1016\/j.xcrm.2022.100543","volume":"3","author":"J Foeng","year":"2022","unstructured":"Foeng, J., Comerford, I. & McColl, S. R. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep. Med. 3, 100543 (2022).","journal-title":"Cell Rep. Med."},{"key":"2327_CR434","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03442-3","volume":"20","author":"T Kouro","year":"2022","unstructured":"Kouro, T., Himuro, H. & Sasada, T. Exhaustion of CAR T cells: Potential causes and solutions. J. Transl. Med. 20, 239 (2022).","journal-title":"J. Transl. Med."},{"key":"2327_CR435","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"2327_CR436","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).","journal-title":"Science"},{"key":"2327_CR437","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-0146-4_17","volume":"2086","author":"H Calderon","year":"2020","unstructured":"Calderon, H., Mamonkin, M. & Guedan, S. Analysis of CAR-mediated tonic signaling. Methods Mol. Biol. 2086, 223\u2013236 (2020).","journal-title":"Methods Mol. Biol."},{"key":"2327_CR438","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40303-z","volume":"14","author":"T Sar\u00e9n","year":"2023","unstructured":"Sar\u00e9n, T. et al. Complementarity-determining region clustering may cause CAR-T cell dysfunction. Nat. Commun. 14, 4732 (2023).","journal-title":"Nat. Commun."},{"key":"2327_CR439","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin. Cancer Res. 25, 2915\u20132924 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2327_CR440","doi-asserted-by":"publisher","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","volume":"5","author":"N Watanabe","year":"2016","unstructured":"Watanabe, N. et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology 5, e1253656 (2016).","journal-title":"Oncoimmunology"},{"key":"2327_CR441","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ymthe.2020.06.004","volume":"28","author":"SA Richman","year":"2020","unstructured":"Richman, S. A. et al. Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo. Mol. Ther. 28, 1600\u20131613 (2020).","journal-title":"Mol. Ther."},{"key":"2327_CR442","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744823","volume":"12","author":"H Lin","year":"2021","unstructured":"Lin, H. et al. Advances in universal CAR-T cell therapy. Front. Immunol. 12, 744823 (2021).","journal-title":"Front. Immunol."},{"key":"2327_CR443","doi-asserted-by":"publisher","first-page":"10303","DOI":"10.1182\/blood-2022-166432","volume":"140","author":"JP McGuirk","year":"2022","unstructured":"McGuirk, J. P. et al. CTX110 allogeneic CRISPR-Cas9-engineered CAR T cells in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): Results from the phase 1 dose escalation carbon study. Blood 140, 10303\u201310306 (2022).","journal-title":"Blood"},{"key":"2327_CR444","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","volume":"27","author":"C Sommer","year":"2019","unstructured":"Sommer, C. et al. Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma. Mol. Ther. 27, 1126\u20131138 (2019).","journal-title":"Mol. Ther."},{"key":"2327_CR445","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med. 29, 422\u2013429 (2023).","journal-title":"Nat. Med."},{"key":"2327_CR446","doi-asserted-by":"crossref","unstructured":"Pan, J. et al. Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial. Nat. Med. (2024).","DOI":"10.1038\/s41591-024-03282-2"},{"key":"2327_CR447","doi-asserted-by":"publisher","first-page":"102147","DOI":"10.1016\/j.tranon.2024.102147","volume":"51","author":"Z Wu","year":"2025","unstructured":"Wu, Z., Wang, Y., Jin, X. & Wang, L. Universal CAR cell therapy: Challenges and expanding applications. Transl. Oncol. 51, 102147 (2025).","journal-title":"Transl. Oncol."},{"key":"2327_CR448","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.17544","volume":"195","author":"K Sanber","year":"2021","unstructured":"Sanber, K., Savani, B. & Jain, T. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br. J. Haematol. 195, 660\u2013668 (2021).","journal-title":"Br. J. Haematol."},{"key":"2327_CR449","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11864-023-01061-8","volume":"24","author":"Y An","year":"2023","unstructured":"An, Y. et al. Off-the-Shelf\u201d Allogeneic CAR Cell Therapy-Neglected HvG Effect. Curr. Treat. Options Oncol. 24, 409\u2013441 (2023).","journal-title":"Curr. Treat. Options Oncol."},{"key":"2327_CR450","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168\u2013182 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR451","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215\u2013229 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2327_CR452","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth, R. E. & Jansen, K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 4, 7 (2019).","journal-title":"NPJ Vaccines"},{"key":"2327_CR453","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40207-y","volume":"14","author":"J Meng","year":"2023","unstructured":"Meng, J. et al. Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation. Nat. Commun. 14, 4505 (2023).","journal-title":"Nat. Commun."},{"key":"2327_CR454","doi-asserted-by":"crossref","unstructured":"Graciotti, M. et al. Deciphering the mechanisms of improved immunogenicity of hypochlorous acid-treated antigens in anti-cancer dendritic cell-based vaccines. Vaccines 8, 271 (2020).","DOI":"10.3390\/vaccines8020271"},{"key":"2327_CR455","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40425-019-0625-x","volume":"7","author":"MM Melssen","year":"2019","unstructured":"Melssen, M. M. et al. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund\u2019s adjuvant in melanoma patients. J. Immunother. Cancer 7, 163 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2327_CR456","doi-asserted-by":"crossref","unstructured":"Patel, S. P. et al. Phase I\/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund\u2019s adjuvant (IFA) for resected high-risk melanoma. J. Immunother. Cancer 9, e003220 (2021).","DOI":"10.1136\/jitc-2021-003220"},{"key":"2327_CR457","doi-asserted-by":"publisher","first-page":"15499","DOI":"10.1021\/acsnano.4c00063","volume":"18","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. Delivery of mRNA encoding interleukin-12 and a stimulator of interferon genes agonist potentiates antitumor efficacy through reversing T cell exhaustion. ACS Nano 18, 15499\u201315516 (2024).","journal-title":"ACS Nano"},{"key":"2327_CR458","doi-asserted-by":"publisher","first-page":"eabc2816","DOI":"10.1126\/scitranslmed.abc2816","volume":"13","author":"L Chen","year":"2021","unstructured":"Chen, L. et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci. Transl. Med. 13, eabc2816 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2327_CR459","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct. Target. Ther. 8, 450 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2327_CR460","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3390\/vaccines10122011","volume":"10","author":"M Gupta","year":"2022","unstructured":"Gupta, M. et al. Recent advances in cancer vaccines: Challenges, achievements, and futuristic prospects. Vaccines 10, 2011 (2022).","journal-title":"Vaccines"},{"key":"2327_CR461","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis, P. D., Ishii, K. J. & Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24, 213\u2013227 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2327_CR462","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer, R. et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat. Med. 26, 1557\u20131563 (2020).","journal-title":"Nat. Med."},{"key":"2327_CR463","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1022496","volume":"12","author":"SS Shaikh","year":"2022","unstructured":"Shaikh, S. S. et al. Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma. Front. Oncol. 12, 1022496 (2022).","journal-title":"Front. Oncol."},{"key":"2327_CR464","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599\u20131611 (2022).","journal-title":"Nat. Med."},{"key":"2327_CR465","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362.e324 (2020).","journal-title":"Cell"},{"key":"2327_CR466","doi-asserted-by":"publisher","first-page":"e003218","DOI":"10.1136\/jitc-2021-003218","volume":"9","author":"J McAuliffe","year":"2021","unstructured":"McAuliffe, J. et al. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. J. Immunother. Cancer 9, e003218 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2327_CR467","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162\u2013168 (2019).","journal-title":"Science"},{"key":"2327_CR468","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148\u20133165.e3120 (2023).","journal-title":"Cell"},{"key":"2327_CR469","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 379, 722\u2013730 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR470","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2327_CR471","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-18-0095","volume":"6","author":"PS Chowdhury","year":"2018","unstructured":"Chowdhury, P. S., Chamoto, K., Kumar, A. & Honjo, T. PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8+ T cells and facilitates anti-PD-1 therapy. Cancer Immunol. Res. 6, 1375\u20131387 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"2327_CR472","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.1158\/0008-5472.CAN-16-0587","volume":"76","author":"MJ Scheffel","year":"2016","unstructured":"Scheffel, M. J. et al. Efficacy of adoptive T-cell therapy is improved by treatment with the antioxidant N-acetyl cysteine, which limits activation-induced T-cell death. Cancer Res. 76, 6006\u20136016 (2016).","journal-title":"Cancer Res"},{"key":"2327_CR473","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00262-018-2120-5","volume":"67","author":"MJ Scheffel","year":"2018","unstructured":"Scheffel, M. J. et al. N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. Cancer Immunol. Immunother. 67, 691\u2013702 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"2327_CR474","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01848-8","volume":"22","author":"W Zhou","year":"2024","unstructured":"Zhou, W. et al. Acetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1+PD1+CD8+ T cell differentiation. Cell. Commun. Signal. 22, 503 (2024).","journal-title":"Cell. Commun. Signal."},{"key":"2327_CR475","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"CH Koh","year":"2023","unstructured":"Koh, C. H. et al. CD8 T-cell subsets: Heterogeneity, functions, and therapeutic potential. Exp. Mol. Med. 55, 2287\u20132299 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2327_CR476","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00412-018-0659-8","volume":"127","author":"X Sun","year":"2018","unstructured":"Sun, X. & Kaufman, P. D. Ki-67: More than a proliferation marker. Chromosoma 127, 175\u2013186 (2018).","journal-title":"Chromosoma"},{"key":"2327_CR477","doi-asserted-by":"publisher","first-page":"653974","DOI":"10.3389\/fimmu.2021.653974","volume":"12","author":"F Di Rosa","year":"2021","unstructured":"Di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-evaluating the use and potentials of Ki-67 for T cell analysis. Front. Immunol. 12, 653974 (2021).","journal-title":"Front. Immunol."},{"key":"2327_CR478","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 114, 4993\u20134998 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2327_CR479","doi-asserted-by":"publisher","first-page":"8941260","DOI":"10.1155\/2016\/8941260","volume":"2016","author":"J Reiser","year":"2016","unstructured":"Reiser, J. & Banerjee, A. Effector, memory, and dysfunctional CD8+ T cell fates in the antitumor immune response. J. Immunol. Res. 2016, 8941260 (2016).","journal-title":"J. Immunol. Res."},{"key":"2327_CR480","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1182\/blood-2002-11-3577","volume":"101","author":"J Geginat","year":"2003","unstructured":"Geginat, J., Lanzavecchia, A. & Sallusto, F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101, 4260\u20134266 (2003).","journal-title":"Blood"},{"key":"2327_CR481","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257\u20131265 (2007).","journal-title":"J. Exp. Med."},{"key":"2327_CR482","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1744946","volume":"9","author":"I Shevchenko","year":"2020","unstructured":"Shevchenko, I. et al. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. Oncoimmunology 9, 1744946 (2020).","journal-title":"Oncoimmunology"},{"key":"2327_CR483","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26134-w","volume":"12","author":"E Schneider","year":"2021","unstructured":"Schneider, E. et al. CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression. Nat. Commun. 12, 5911 (2021).","journal-title":"Nat. Commun."},{"key":"2327_CR484","doi-asserted-by":"publisher","first-page":"eabi8618","DOI":"10.1126\/sciadv.abi8618","volume":"8","author":"E Sanz-Garcia","year":"2022","unstructured":"Sanz-Garcia, E., Zhao, E., Bratman, S. V. & Siu, L. L. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. Sci. Adv. 8, eabi8618 (2022).","journal-title":"Sci. Adv."},{"key":"2327_CR485","doi-asserted-by":"crossref","unstructured":"Dang, D. K. & Park, B. H. Circulating tumor DNA: Current challenges for clinical utility. J. Clin. Invest. 132, e154941 (2022).","DOI":"10.1172\/JCI154941"},{"key":"2327_CR486","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker, J. D. et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J. Clin. Oncol. 36, 1631\u20131641 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2327_CR487","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon, D. W., Bratman, S. V., Chan, S. M. & Siu, L. L. Circulating tumor DNA and liquid biopsy in oncology. Nat. Cancer 1, 276\u2013290 (2020).","journal-title":"Nat. Cancer"},{"key":"2327_CR488","doi-asserted-by":"crossref","unstructured":"Alsaiari, S. K. et al. CRISPR\u2013Cas9 delivery strategies for the modulation of immune and non-immune cells. Nat. Rev. Mater. (2024).","DOI":"10.1038\/s41578-024-00725-7"},{"key":"2327_CR489","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy, S. P. et al. Non-viral precision T\u2009cell receptor replacement for personalized cell therapy. Nature 615, 687\u2013696 (2023).","journal-title":"Nature"},{"key":"2327_CR490","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020)."},{"key":"2327_CR491","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2327_CR492","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal, S. et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity 56, 2388\u20132407.e2389 (2023).","journal-title":"Immunity"},{"key":"2327_CR493","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-023-06733-x","volume":"624","author":"P Zhou","year":"2023","unstructured":"Zhou, P. et al. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. Nature 624, 154\u2013163 (2023).","journal-title":"Nature"},{"key":"2327_CR494","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj4008","volume":"375","author":"R Schmidt","year":"2022","unstructured":"Schmidt, R. et al. CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science 375, eabj4008 (2022).","journal-title":"Science"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02327-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T18:04:04Z","timestamp":1767463444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02327-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":494,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2327"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02327-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}